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Summary 
Angiogenesis is a process where new capillaries are formed from pre-existing ones. 
It involves endothelial cell activation, extracellular matrix degradation, endothelial cell 
proliferation and migration and fusion with neighboring sprouts. Stabilization and lumen 
formation of the new capillary are the last steps of sprouting angiogenesis. Sprouting 
angiogenesis is one the most prominent mechanism of tumor vascularization and is a 
growth factor-driven process with FGF2 and VEGF being the key regulators. 
The mTOR signaling pathway is a central cellular regulator and consists of two 
distinct complexes with individual roles and functions: mTORC1 and mTORC2. mTORC1 
is a regulator of cell proliferation, protein synthesis, and growth and conveys signals from 
growth factors, ATP and O2 levels. Until now mTORC2 is known to mediate growth factor 
signaling and regulates cell survival and cytoskeleton reorganization. In all cell types 
mTORC1 is sensitive to Rapamycin-based inhibition, while mTORC2 is not. However in 
certain cell type such as endothelial cells mTORC2 can be inhibited by prolonged 
Rapamycin treatment. In xenograft tumor models Rapamycin treatment reduced tumor 
growth and tumor vascularization. In the majority of these studies dual inhibition of both 
mTOR complexes results in greater inhibition of tumor growth and vascularization than 
mTORC1 inhibition alone, pointing to a specific role of mTORC2 in tumor vascularization. 
The distinct roles of mTORC1 and mTORC2 in angiogenesis have not been elucidated due 
to the absence of specific mTORC2 inhibitors. 
In this thesis we examine the role of endothelial mTORC2 in physiologic and 
FGF2-induced angiogenesis. mTORC2 is a multi-protein complex composed by mTOR, 
Rictor and other accessory proteins. We employed an endothelial-specific and Tamoxifen-
induced Rictor
iΔec 
mouse that ideally leads to the ceasing of mTORC2 signaling in the 
endothelium. We monitored FGF2 induced angiogenesis in vivo with intravital microscopy 
of the dorsal skinfold chamber and FGF2 Matrigel plug implantation. We observed that 
ceasing mTORC2 signaling had no impact in already developed vasculatures and in wound-
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healing angiogenesis. Rictor
iΔec 
mice showed limited FGF2-induced capillary diameter 
increase, in resident skin capillaries of the skin muscle vasculature and exhibited 
differential remodeling architecture in the skin muscle vasculature. Impaired neo-
angiogenesis in FGF2-loaded Matrigel plugs was also seen in Matrigel plugs of the 
Rictor
iΔec 
mice. Thus, we demonstrate for the first time direct evidence that endothelial 
mTORC2 signaling is crucial for FGF2 induced angiogenesis. 
This thesis also analyses the efficiency and stability of Rictor knockout induction in 
the endothelium and the optimization of multiple endothelial cell isolation techniques, 
which led in the optimization of future uses of Cre-Lox based deletion techniques in the 
laboratory.  
In conclusion the present thesis demonstrates for the first time the role of 
endothelial mTORC2 in FGF2-induced angiogenesis, by regulating capillary diameter, 
vasculature architecture and neo-angiogenesis. A mechanistic insight is further needed to 
reveal the molecular and cellular aspects of this regulation  
 
 
 
 
 
 
 
 
 
7 
 
Zusammenfassung   
Die Angiogenese ist ein Prozess, bei welchem neue Kapillaren aus bereits 
bestehenden gebildet werden. Angiogenese beinhaltet unter anderem 
Endothelzellaktivierung, Abbau der extrazellulären Matrix, Endothelzell Proliferation und 
Migration und Fusion von entstehenden Kapillarspossen mit Benachbarten. Stabilisierung 
und Lumenbildung der neuen Kapillaren sind die letzten Schritte der sprossenden 
Angiogenese. Diese Art der Angiogenese ist einer der prominentesten Mechanismen der 
Tumorgefäßbildung. Sprießende Angiogenese ist ein Wachstumsfaktor getriebener Prozess 
mit FGF2 und VEGF als den wichtigsten Initiatoren.  
Der mTOR-Signalweg ist ein zentraler intrazellulärer Regulierung Mechanismus 
und besteht aus zwei verschiedenen Komplexen mit individuellen Rollen und Funktionen: 
mTORC1 und mTORC2. mTORC1 ist Regulator der Zellproliferation, der Proteinsynthese 
und des Wachstums und prozessiert Signale von Wachstumsfaktoren, Energie und 
Sauerstoff Niveaus. Bis jetzt ist bekannt, dass mTORC2 durch Wachstumsfaktoren aktiviert 
wird, das  Überleben der Zelle reguliert und das Zellskelett reorganisiert. mTORC1 ist der 
Komplex, welcher primär empfindlich gegenüber Hemmung durch Rapamycin ist. 
Besonders in Endothelzellen kann aber auch der mTOR Komplex 2 bei längerer 
Behandlung durch Rapamycin gehemmt werden. In Xenograft Tumormodellen reduziert 
Rapamycin-Behandlung das Tumorwachstum und die Neubildung der Tumorgefäße. Die 
Hemmung beider mTOR Komplexe mit neueren Dual-Inhibitoren führt zu einer stärkeren 
Inhibition des Tumorwachstums und der Gefäßneubildung. Dies deutet auf spezifische und 
unterschiedliche Funktionen der beiden mTOR Komplexe in der Angiogenese.    
In dieser Arbeit untersuchen wir die Rolle des mTOR Komplexes 2 im Endothel 
während der physiologischen und FGF2 induzierten Angiogenese. mTORC2 ist ein 
Multiproteinkomplex von mTOR, Rictor und anderen zusätzlichen Proteinen. Zu diesem 
Zweck induzierten wir eine mTORC2 Defizienz  in der Maus durch Tamoxifen-induzierte 
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Deletion des essentiellen mTORC2 Regulationsproteins Rictor im Endothel (Rictor
iΔec
 
Maus) und überwachten und analysierten die Angiogenese in vivo mittels 
Intravitalmikroskopie der Rückenfaltenkammer und von Matrigel Plug Implantation.  
Wir beobachteten, dass Defizienz von mTORC2 keine Auswirkungen in bereits 
entwickelten Blutgefäßen im Panniculus Carnosus hatte und keine Veränderungen in der 
Angiogenese zeigte, welche durch Wundheilungsprozesse initiiert wurde. 
Interessanterweise beobachteten wir, dass die Stimulation des Gefässbettes im Panniculus 
Carnosus mit einer hohen Dosis von FGF2 die induzierte Zunahme der Kapillar-
Durchmesser in Rictor
iΔec
 Mäusen begrenzt und im Gegensatz zu Kontrollmäusen sich die 
Gefässarchitektur der Hautkapillaren einem geordneten Umbau oder Remodeling 
unterzieht. Ebenfalls wurde eine stark verminderte Neo-Angiogenese in mit FGF2 
versetzten Matrigel Plugs in Rictor
iΔec
 Mäusen beobachtet. In dieser Arbeit beschreiben wir 
folglich die erste direkte Beobachtung, dass mTORC2 Signalisierung im Endothel von 
entscheidender Bedeutung für FGF2 induzierte Angiogenese ist. Des Weiteren wird mit 
dieser Doktorarbeit eine eingehende Analyse der Effizienz von Induktion des Rictor 
Knockouts im Endothel durchgeführt und mehrere Endothelzell-Isolationstechniken 
optimiert. 
Abschließend zeigt diese Arbeit  zum ersten Mal eine spezifische Funktion des 
Signalkomplexes mTORC2 im Endothel in FGF2 induzierter Angiogenese, charakterisiert 
durch Regulation des Kapillardurchmessers, Remodeling des bestehenden Gefässbettes und 
Effizienz von Neo-Angiogenese. Sicherlich werden zukünftige Experimente in Rictor 
knockout Endothelzellen und in einem verbesserten transgenen knockout approach in vivo 
dazu beitragen eine mechanistische Einsicht zu erlangen um die molekularen und zellulären 
Aspekte dieser mTORC2–spezifischen Rolle in der Angiogenese zu offenbaren.  
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1. INTRODUCTION 
1.1 Blood vessels and the cardiovascular system  
The cardiovascular system comprises of the heart, the blood vessels and the 
circulating blood. The heart functions as a double pump, with a left and a right part. The 
right compartment of the heart collects oxygenated blood from the lungs and forwards it to 
the body. The left part of the heart collects the blood from the vein and returns it to the 
lungs to be re-oxygenated (1). The blood vessels and the capillaries network all the body so 
blood reaches every tissue. Vessels and capillaries have distinct structures. Capillaries 
consist of an endothelial monolayer, fully or partially covered by pericytes. The big vessels 
are composed by three layers; the tunica intima, the tunica media and the tunica adventitia. 
The tunica intima is the innermost layer of the artery wall and comes into contact with 
flowing blood. The tunica intima is composed of a monolayer of endothelial cells and is 
surrounded by the tunica media, which is a layer of smooth muscle cells (SMC) embedded 
in a rich extracellular matrix containing collagen, elastin, and proteoglycans. The outer 
layer is the tunica adventitia, which again is composed of a rich extracellular matrix of 
collagen which contains myofibroblasts. Both the tunica media and the tunica adventitia 
vary in their composition and thickness according to the shear stress of the blood flow (2).  
  
 
 
 
 
Figure 1. Structure of a typical vessel and capillary. (A) The three individual layers tunica intima, tunica 
media, and tunica adventitia. (B) Typical capillary with the endothelial monolayer and pericyte covering the 
basal lamina (Humans Anatomy, Pearson Education Inc. 2011). 
 
A B 
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The cardiovascular system is one of the most important systems in higher 
organisms, since it delivers oxygen and nutrients to the tissues, enables gas exchange, and 
clears the metabolic waste (3, 4). Furthermore, it has multiple functions, also in the adult 
body, by controlling the homeostasis, body temperature and the delivery of the immune 
defensive system in the positions needed (5). Accordingly, the cardiovascular system is the 
first to develop in a growing embryo. 
1.2. Blood vessel development  
 In the early embryo the first vessels emerge from precursor cells, the hemangioblasts, 
that differentiate into endothelial cells and hematopoietic cells creating the first blood 
containing vascular tubes by a process called vasculogenesis (3, 6).  
 Oxygen and metabolic needs of the developing tissues stimulate the expansion of the 
initial vascular plexus by sprouting angiogenesis, a process were new capillaries and vessel 
emerge and develop from pre-existing vessels (3,7,8). Maturation of the new capillaries 
occurs by recruitment of pericytes that cover the ab-luminal surface of the endothelial cells 
and stabilize the capillary. Further recruitment of smooth muscle cells and subsequent 
vascular remodeling are the hallmarks of arteriogenesis. Regression of some new capillaries 
will also occur in the context of remodeling and optimization of the new capillary bed 
(3,4,9). Intussusceptive angiogenesis, a different mechanism than sprouting, also 
contributes to the expansion of the vascular plexus. 
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Figure 2: Schematic representation of tissue vascularization during development. (A) Hemangioblasts and 
precursor cells create the initial vascular plexus via vasculogenesis. The vascular plexus expands to meet the 
oxygen and metabolic demands either by sprouting angiogenesis (B) or intussusception (C) (10). 
 
 
1.3. Angiogenesis 
1.3.1. Sprouting angiogenesis 
All blood vessels are lined with a thin layer of simple epithelium known as 
endothelium, that keeps blood cells inside of the blood vessels as a permeability barrier and 
prevents clots from forming (11). Sprouting angiogenesis is a very well described 
morphogenic process, tightly regulated on the cellular and molecular level (7), that begins 
with activation of the capillary endothelium when pro-angiogenic stimuli prevail over anti-
angiogenic mediators. Activated endothelial cells initiate angiogenesis in response to 
hypoxia or tissue-injury ischemia by producing Nitric Oxide (NO) through endothelial 
Nitric Oxide Synthase (eNOS), leading to vasodilation and increased permeability of the 
A 
B 
C 
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endothelium. NO modulates the balance of pro- and anti-angiogenic factors and increases 
permeability of the endothelium allowing the endothelial cells to degrade the Extracellular 
Matrix (ECM) and migrate, creating a new sprout (12,13). 
1.3.2. The role of Vascular Endothelial Growth Factor (VEGF)  
During sprouting angiogenesis endothelial cells differentiate in tip and stalk cells. 
The endothelial cells that are exposed to higher concentrations of VEGF can change their 
quiescent phenotype and transform into an activated cell with expanding philopodia called 
tip cells (14). The tip cells are migrating cells and drive the new sprout away from the 
maternal vessels. The adjutant to the tip cell, proliferating endothelial cells that elongate the 
new sprout are called stalk cells (14).  
VEGF is the most important and endothelial-specific angiogenic growth factor that 
stimulates capillary growth through sprouting angiogenesis (15). The distribution of VEGF 
in the matrix affects the pattern of vascular branching (16). Differential affinity of VEGF 
for the extracellular matrix creates gradients that are essential for tip/stalk cells fate 
determination, a selection force for the endothelial cells that are exposed to locally different 
concentration of VEGF. Cells exposed to the highest concentration of the VEGF gradients 
are selected as tip cells (14). On the other hand, the determination of the stalk cells is not 
dependent on the gradients, but on the actual local concentration of VEGF (14,17). In both 
tip and stalk cells VEGF signals through its receptor VEGFR2 however different signaling 
pathways regulating the fate of the cells are translated into different cell behavior (8,18). 
1.3.3. Tip/stalk cell fate determination 
Investigation of the tip/stalk cell fate determination pathway in zebrafish and mouse 
embryonic retina revealed the essential role of Notch/Delta ligand 4(Dll4) signaling 
downstream of VEGF/VEGFR2 pathway (8,19,20). 
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The VEGF gradient induces increased signaling of VEGFR2 in a tip endothelial 
cell, resulting in the expression of Dll4 on the surface of this cell (21-24). The up-regulation 
of Dll4 in the tip cell activates Notch signaling in the adjutant stalk cell, which become less 
sensitive to VEGF and reduce Dll4 expression levels. The stalk cell reduces the expression 
of VEGFR2, however increases levels of both soluble VEGFR1 (sVEGFR1) and 
membrane-bound VEGFR1 (mVEGFR1). This profile of VEGF receptors makes the stalk 
cell less responsive to VEGF, since sVEGFR1 and the mVEGFR1 have higher affinity for 
VEGF and display reduced tyrosine kinase activity (25-29). The increased presence of both 
mVEGFR1 and sVEGFR1 sharpens the differences in local VEGF concentration and 
promotes the tip/stalk cell selection process (30, 31). The balance between VEGFR1 and 
VEGFR2 regulates the tip/stalk cell fate determination under the control of Notch/Dll4 
signaling pathway (32). Endothelial cells compete for the position of the tip cells and this 
competition is based on the ratio of VEGR1/VEGFR2 (33).The fate of endothelial cells is 
not definite and the roles between the tip and the stalk cells can change due to the plasticity 
of the process. Thus, Notch signaling functions as control point and can reduce exaggerated 
tip cell formation that would otherwise lead to unsuccessful angiogenesis.  
VEGF receptor 3 (VEGFR3, Flt4) is another member of the VEGF receptor family 
known for its role to induce lymphangiogenesis (34). The VEGFR3 is gaining attention due 
to its expanding importance in sprouting angiogenesis in the last years. VEGFR3 has been 
shown to be up-regulated in the tip cells and it can induce sprouting angiogenesis in the 
absence of VEGFR2/VEGFA signaling (35). This implies that tip cell formation and 
sprouting is not a VEGFR2-restricted process. Further studies revealed that 
VEGFR3/VEGFC signaling pathway promotes the conversion of tip cell to a stalk cell in 
areas of neighboring sprouts fusion. VEGFC is localized at the fusion areas and secreted by 
macrophages that localize at the leading front of the spout and sprout fusion areas (36,37). 
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Figure 3: The importance of VEGF gradients and the crosstalk of VEGF/VEGFR2-Notch/Dll4 pathway 
(A) VEGF gradients promote sprouting and tip/stalk cell fate determination by the crosstalk of VEGF/VEGFR2, 
which up-regulates Dll4 in the tip cell. The tip cell promotes stalk cell phenotype in the adjusting cells by Notch 
activation via Dll4. (B) VEGF gradients are needed to orchestrate guidance queues. Diffused VEGF is unable to 
provoke sprout outgrowth. (C) Notch signaling acts as negative regulator of tip cell formation and loss of 
Dll4/Notch signaling leads to exaggerated sprouting but not to functional capillaries. Inhibition of Notch in the 
stalk cells promotes tip cell phenotype  and remodeling (17) (22).  
 
 
The regulation of VEGFR3 in tip and stalk cells is not yet clarified. There are 
opposing in vivo and in vitro data on how Notch/Dll4 signaling regulates the VEGFR3 
expression pattern in the emerging sprout (35,38,39). Most recent data suggest that 
VEGFR3 can be also regulated by VEGFR2-VEGF and Notch/Dll4 signaling but the 
mechanism is not fully understood. VEGFR3 seems to be up-regulated in cells with low or 
absent Notch signaling and the receptor seems to be able to sustain deregulated 
angiogenesis even in the absence of VERGR2 signaling (38).  
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In the same study in conditional transgenic murine retinas and in contrast with 
previous knowledge, Benedito et al. demonstrated that the levels of Dll4 are not dependent 
only on VEGFR2 signaling and that endothelial cell fate is not only relying on the 
VEGFR2/VEGFA-Notch/Dll4 relation and interplay (38). Thus, angiogenic sprouting may 
take place without the VEGFR2, which so far has been considered as main transducer of 
this process. 
1.3.4. Sprout fusion and lumen formation 
As the tip endothelial cell migrates towards the angiogenic stimuli it still remains 
attached and connected to the parental vessel through the stalk cells. The stalk cells may not 
have migratory capacity, however exhibits increased proliferation and thereby extends the 
growing sprout (4,14). The reorganization of the stalk cells in the growing sprout creates a 
lumen, which will be perfused by the parental vessel. Finally, most of the new sprouts find 
each other, connect and fuse to create new capillaries. Unfused and unnecessary sprouts 
regress (4).  
1.3.5. Capillary and vessel maturation and stabilization. 
After two new neighboring sprouts fuse and merge to create one capillary, 
maturation increases its stability and function by the recruitment of pericytes, vascular 
smooth muscle cells, and the deposition of extracellular matrix to form a new basement 
membrane. Capillary maturation is essential for the regulation of the capillary diameter, 
contractility, and resistance to blood flow and shear stress (40-42).  
PDGF-BB is a growth factor secreted by endothelial cells and it is one of the 
essential growth factors that stimulate pericyte recruitment. PDGF is mainly secreted in 
sites with active angiogenesis, possibly by tip endothelial cell (43-45). Secreted PDGF-BB 
possesses a heparin sulfate binding motif, which allows the growth factor to anchor in the 
extracellular matrix and form a spatial distribution in close proximity with the endothelial 
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cells of the newly emerged endothelial tube. Pericyte are attracted via PDGFR activation to 
directly cover and interact with endothelial cell and stabilize the tube (41,43,45,46). 
Angiopoietin1 (Ang-1)-Tie-2 signaling pathway has a great importance in 
stabilization of immature vascular tubes. Ang-1 is secreted by pericytes and binds to the 
endothelial receptor Tie-2. Ang-1 provides a stabilizing signal to endothelial cells and 
promotes the coverage of the endothelial tube with pericytes. Importantly this signaling 
pathway hampers endothelial cells proliferation and promotes endothelial quiescence (47-
52). Mechanistically Ang-1-Tie-2 signaling promotes capillary stabilization by regulation of 
endothelial tight junctions, the accumulation and distribution of Ve-cadherin and the 
rearrangement and stabilization of the endothelial cell cytoskeleton (47,53,54). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Capillary and vessel maturation (A) Nascent endothelial tube that will mature into a functional 
capillary or vessel. (B) Mature and functional capillary embedded into basement membrane and partial or fully 
covered with pericytes. (C) Arterioles and vessels have different mode of maturation. Arterioles are fully 
covered by SMC while venules are partially covered. Elastic lamina is present in both arterioles and venules. 
(40)  
 
 
Maturation of the neo-vessels also includes the deposition of a new basement 
membrane, which offers stability, elasticity, and support in the capillaries and vessels (40, 
42). In vitro studies revealed that the assembly and deposition of new basement membrane 
 
 
19 
 
after the formation of a new capillary is dependent on both endothelial cells and pericytes 
(55,56). Pericytes help in the maturation and the deposition of new basement membrane by 
inhibiting endothelial matrix metallo-proteases (MMPs), which are secreted during 
sprouting angiogenesis in order to create space for the migration of the new sprout. Pericyte 
MMP inhibitors TIMP2 and TIMP3 directly suppress the endothelial MMPs and indirectly 
tube formation and angiogenesis (55-60). 
1.3.6. Intussusception: an alternative mode of angiogenesis 
Besides spouting angiogenesis, intussusception, i.e., capillary or vessel splitting, is 
an additional mode of vascular expansion of an already formed vasculature without the 
necessity of endothelial cell proliferation and recruitment of several other cells types (61). 
During intussusception a pillar is created on the capillary wall, which extends inside the 
intraluminal space, separates and then longitudinally splits one capillary in two. (62-64). 
Intussusception contributes to the microvascular expansion of vascular beds and it is 
essential for the growth of an initial capillary plexus and the creation of a physiological 
vascular tree. It contributes to the hierarchical branching of vascular trees in an organ-
specific way in order to meet metabolic and shear stress demands by amplifying the 
vascular surface and volume (61,65-67). Optimization of the flow properties of a vascular 
network is mediated by intussusceptive branching remodeling (IBR). This process provides 
the optimum geometry and architecture of a vascular bed in order to meet blood flow 
demands of each different tissue (61,63,67). 
Sprouting angiogenesis and intussusceptive angiogenesis exist in combination in all 
vertebrates and they work in the direction of producing the optimal vascular bed needed for 
each tissue and organ. Intussusception is a plastic and energy-economic process that focuses 
more on the architecture and is regulated mainly by hemodynamic factors. This mechanism 
of vascular expansion is also implicated in tumor angiogenesis. The molecular factors that 
regulate intussusception are not yet clear (61,63).  
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1.4. Angiogenesis in health and disease 
Angiogenesis is not a restricted process during embryo development and organ 
growth, it also occurs physiologically during tissue repair and wound healing in adults, 
adipose or muscle tissue expansion and in the reproductive cycle of the adult females (3) 
There are also pathologies that are characterized by extensive and uncontrolled 
angiogenesis, which is stimulated by unbalanced angiogenesis activators and inhibitors. 
Cancer development is one of the diseases that induces and is dependent on excessive and 
uncontrolled microvessel growth (7,8,68). Diabetes and rheumatoid arthritis are two more 
examples of diseases that promote and are worsened by excessive and uncontrolled 
angiogenesis (3).  
1.4.1. Angiogenesis as a therapeutic target for cancer and tumor growth 
In 1971 Judah Folkman recognized angiogenesis as an integral part of tumor 
growth and development and suggested that hampering angiogenesis in tumors could 
potentially lead to tumor stasis and regression (69). The understanding and the dissection of 
the mechanisms of physiological angiogenesis have been a valuable tool to design anti-
angiogenesis drugs which have been brought to trial the past 10 years (7). 
Tumor angiogenesis is triggered by hypoxia. The initial tumor cells proliferate and 
create a mass that can be fed and oxygenated by diffusion from the host vessels. When this 
tumor mass exceeds a volume of about 2mm
3 
hypoxia is occurring in the core of the tumor 
mass. This stimulates the expression of angiogenic molecules and growth factors leading to 
sprouting angiogenesis of the host vessel that invade the tumor mass and metabolically 
support its growth (7,70,71).  
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Figure 5: Tumor induced sprouting angiogenesis. Hypoxia occurring in the core of the tumor 
stimulates the secretion of VEGF, FGF and PDGF attracting new sprouts from the host vasculature in 
order to maintain their growth and survival. Endothelial and pericyte progenitor cells are also attracted 
to the site of active angiogenesis and contribute to tumor vascularization via vasculogenesis (7).  
 
 
 
Sprouting angiogenesis is not the only way that a tumor can use to obtain its 
vascularization. Intussusceptive angiogenesis has been also observed in growing tumors 
were sprouting angiogenesis is hampered by chemotherapy or targeted anti-angiogenesis 
treatments (72).  
Tumors also employ alternative means of vascularization such as host vessel co-
option and vasculogenesis. Vascular co-option describes the ability of tumor cells to 
proliferate and migrate along host vessels, using them as survival rails which provide 
oxygen and nutrients (69). On the other hand the hypoxic conditions within the tumor 
attract endothelial and pericyte progenitor cells that can contribute to the vascularization of 
the tumor. Last but not least, tumor cells themselves can contribute to their own 
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vascularization by vascular mimicry. Tumor cells or tumor stem cells can express cancer 
and endothelial specific markers and can be incorporated or create vessels and capillary-like 
tubes and structures (7,70,73,74). 
 
 
 
 
 
 
 
 
 
Figure 6: Different types of tumor vascularization. (A) Major mechanism of tumor vascularization by 
sprouting angiogenesis of the host vessels and capillaries invading the tumor mass. (B) Tumor cells or tumor 
stem cells mimic endothelial cells and are incorporated in tumor capillaries or create tube-like structures within 
the tumor. Tubular wall cells co-express endothelial or tumor surface markers. Bone marrow cells are also 
incorporated in the tumor capillaries via vasculogenesis. (C) Tumor cells migrate around host vessels via co-
option using them as survival rails supporting their growth (75) 
 
 
The cellular and molecular mechanisms of sprouting angiogenesis that have been 
revealed the last years apply also to tumor sprouting angiogenesis. This insight led to the 
development of targeted anti-angiogenesis treatments that focus on essential pathways such 
as the VEGF/VEGFR pathway, the PDGF/PDGFR pathway and the signaling via receptor 
tyrosine kinases (RTK) (7,74,76).  
These anti-angiogenesis approaches for tumor regression showed hopeful results 
and some angiogenesis inhibitors are approved as treatments for specific types of cancers. 
However, resistance mechanisms in anti-angiogenesis treatments arise mainly due to the 
induction of secondary hypoxia by vessel regression, which leads to the up-regulation of 
alternative growth factor signaling pathways, mainly FGF2. This induces alternative 
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molecular mechanisms to maintain tumor vascularization and oxygen supply (7,70,73,77, 
78).  
1.5. Fibroblast growth factor 2: The orchestrating angiogenic growth factor 
Fibroblast Growth Factor 2 (FGF2) is a very well characterized and potent 
angiogenic inducer first described in 1974 and is implicated in physiological, pathological 
and tumor angiogenesis (79,80). FGF2 possesses pleiotropic activities by regulating 
multiple cells types and acting synergistically with other growth factors to promote 
angiogenesis and vascular remodeling (80,81).  
Tissues and vascular beds are exposed to FGF2 during trauma, inflammation or 
tumor growth; however its secretion mechanism is unclear (81). It is speculated that FGF2 
is released by damaged or necrotic cells, since no specific cell-mediated secretion 
mechanism has been established and the only available data indicate that its secretion is 
independent from the Endoplasmic Reticulum-Golgi system and that the FGF2 protein 
lacks a secretion peptide (82,83).  
FGF2 possesses high affinity for glycosaminoglycans and can bind to heparin 
sulfate proteoglycans in the extracellular matrix keeping the growth factor inactive (83,84). 
During angiogenesis, the FGF2-binding protein (FGF2-BP) interacts with the anchored 
FGF2 in the ECM, decreasing its affinity for the heparin sulfate proteoglycans and releasing 
it as an active form (84,85). FGF2 exerts its biological functions through binding to FGFR1, 
a tyrosine kinase receptor, causing a homodimerization of the receptor, which then signals 
by phosphorylating-specific tyrosine residues (81,86). 
 FGF2 exerts its angiogenic functions by inducing other growth factor pathways in 
endothelial cells and pericytes, promoting endothelial cells proliferation, resistance to 
apoptosis, increased cell motility and migration (80,82). FGF2 is known to induce VEGFA 
and VEGFR2 expression in endothelial cells, promoting endothelial and stromal cells 
proliferation (87-90). Several in vivo and in vitro data highlight the necessity of the cross-
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talk between FGF2/VEGF signaling, suggesting that FGF2 depends on the VEGF signaling 
in order to induce angiogenesis. After the VEGF signaling cascade is initiated, FGF2 
appears not to be required to drive endothelial cell proliferation and angiogenesis (91-94). 
This crosstalk between the two growth factors does not necessarily translate in regulation of 
the same genes involved in angiogenic processes. VEGF and FGF2 both regulate genes that 
modulate cell adhesion, cell growth, DNA damage repair, apoptosis and activity of 
transcription factors, i.e., Tie-2 precursor, Tie-1, VEGFC, VEGFR1, MCP1, and ERK1. On 
the other hand there are genes differentially regulated by these growth factors such as 
VCAM-1, β-CATENIN, E-Cadherin, IGFR2, MAP2K3, phospholipase C, IGF, 
ERK3/MAPK4 (95).  
FGF2 and VEGFA induce different patterns of neo-vasculatures in Matrigel plugs: 
FGF2-induced angiogenesis creates endothelial tubes which are partially covered by 
pericytes and actively perfused. On the other hand VEGFA alone failed to induce the 
generation of functional capillaries in Matrigel plugs and only the combination of both 
growth factors resulted in a functional, not leaky and mature neo-vasculature (96). 
Similarly, in a corneal angiogenesis assay FGF2 induced the formation of well-structured 
and functional capillaries that were well fused. On the other hand VEGF resulted in pseudo-
hemorrhagic phenotype and irregular fusion patterns (97). These finding may be explained 
by the fact that FGF2 acts also on the PDGF-BB/PDGFR system and on the Ang-1/2-Tie-2 
system that are involved in vessel maturation (96,98-100).  
1.6. mTOR signaling pathway 
Cell proliferation and growth are regulated through different signaling pathways, of 
which the mammalian target of Rapamycin (mTOR) signaling pathway is central and of 
major importance (101). 
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Two distinct multi-protein complexes lie at the core of the mTOR signaling 
pathway, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 and 
mTORC2 sense and respond to different extracellular stimuli, have different regulatory 
mechanisms and distinct substrates that at the end regulate different cellular actions and 
processes (102, 103). They have the same core protein mTOR, which is a highly conserved 
serine/threonine kinase. The two complexes share accessory proteins, mLST8 and DEPTOR 
(104-106). Additionally, mTORC1 contains regulatory binding proteins Raptor and 
PRAS40 (107-110). mTORC2 besides the common protein scaffold contains the regulatory 
binding proteins Rictor, mSIN1, and PRR5/Protor (104, 111-114). Rictor in collaboration 
with mSIN1 promotes the structural stability of the full complex (111,115-117).  
Rictor, mSIN1, and Raptor are essential parts of the two mTOR complexes and 
have distinct sensitivity in Rapamycin treatment. Once Rapamycin enters the cell it binds to 
FKBP-12 forming a complex that interacts and inhibits mTORC1 through allosteric 
conformational changes of the kinase domain or by changing the structural integrity of the 
full complex (118-121). In the majority of cell types mTORC2 is not sensitive to 
Rapamycin-based inhibition. However, and most evidently in endothelial cells, long term or 
high dose of Rapamycin treatment induces mitigation of mTORC2 signaling. It is unclear 
why this distinction in certain cell types exists. Mechanistically, the inhibition of mTORC2 
signaling by Rapamycin relies on the reduced bioavailability of mTOR; mTORC2 assembly 
is hindered since the Rapamycin-FKBP12 binds most of the available free mTOR in 
mTORC1 (104,112,122,123) 
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Figure 7. The mTOR signaling pathway (102) 
 
1.6.1. mTORC1  
mTORC1 has been shown to regulate anabolic processes such as protein synthesis, 
lipid synthesis, and metabolism. These are cellular functions that are central for survival. 
mTORC1 conveys signals from growth factors, stress, O2   levels, ATP, and amino acids, 
which induce anabolic or katabolic pathways (101,102). The major upstream regulator of 
mTORC1 activity when stimulated by growth factors is the heterodimer tuberous sclerosis 
complex 1 and 2 (TSC1/TSC2 complex). Binding of a growth factor to its surface receptor 
activates the signaling cascade of the PI3K/Ras pathway that leads to the phosphorylation 
of TSC1/2 by Akt and ERK1/2 pathway. This phosphorylation inactivates TSC1/2 leading 
to the activation of mTORC1 via GTP-Rheb protein (124-129). Inflammatory cytokines, 
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ATP, and O2 levels also activate mTORC1 via TSC1/2 - however there is also an Akt 
activating path that is independent from TSC1/2 (110,130,131) 
The major activity mTORC1 signaling is activation of cell growth by protein 
synthesis. The effectors downstream of mTORC1 are well established. mTORC1 has a 
kinase activity that phosphorylates eIF-4E-BP1 (eukaryotic initiation factor E4 binding 
protein). eIF-4E is an initiation factor for mRNA translation. Phosphorylation via S6K of 
eIF-4E-BP binding protein does not allow the binding with eIF-4E, which now can actively 
participate in protein translation (132-134). S6K1 kinase is the direct target of mTORC1, 
which is also regulating mRNA synthesis and translation (102). mTORC1 also positively 
regulates the synthesis of lipids and ATP production in hypoxic conditions by up-regulating 
glycolysis. All these processes boost cell proliferation and survival (101,102). 
1.6.2. mTORC2  
So far, it has been established that mTORC2 is activated only by growth factor 
signals and  not by nutrient and energy levels, or O2 saturation (103). mTORC2’s major and 
initially described substrate is Akt, a kinase with central activity for almost all cellular 
functions. Phosphorylation of Akt by mTORC2 at Serine 473 induces its translocation to 
cellular membranes in association with mTORC2 (135, 136). This activity of mTORC2 
provides the maximal and optimal activation of Akt, which in turn phosphorylates its 
targets FoxO1/3a (111,117,137). Several researchers suggested that the activation of 
FoxO1/3a is specifically dependent on mTORC2 mediated Akt Ser473 phosphorylation. 
mTORC2 also phosphorylates Akt in Ser450, which is not a constitutive reaction but is 
needed when nascent Akt exits the ribosome as a polypeptide. This phosphorylation induces 
conformational changes, enhancing Akt stability (135,138,139).  
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mTORC2 also acts as a specific kinase of Protein Kinase C alpha (PKCα) and 
Serum and Glucocorticoid-induced Kinase 1 (SGK1). PKCα is phosphorylated by 
mTORC2 and promotes its maturation, folding and stability by recruiting Hsp90 chaperon 
(103,140,141). SGK1 is also phosphorylated by mTORC2, which allows its optimal 
activation, resulting in FoxO1/3a phosphorylation and activation (142,143). The activation 
of mTORC2 is associated with cytoskeleton and actin rearrangement, and cell migration. 
The molecular mechanism of mTORC2 regulation of the cytoskeleton still remains to be 
elucidated (104, 112). The association of mTORC2 with the ribosomes may suggest a direct 
regulatory role in protein synthesis (144,145). Indirectly, the full activation of Akt by 
mTORC2 can interfere with TSC1/2 activation via Akt and, by consequence, with 
mTORC1 signaling, which regulates protein synthesis and other metabolic processes. While 
mTORC1 is very well studied regarding upstream regulators and downstream effectors, 
mTORC2 is less studied and little is known about its contribution on important 
physiological and pathological processes. 
 
1.6.3. The implication of mTOR signaling pathway in angiogenesis 
The investigation and characterization of the mTOR signaling pathway has revealed 
its role in fundamental cellular processes including cell survival, proliferation, and 
apoptosis by conveying signals from the extracellular environment. The discovery of 
Rapamycin and its known function in mTORC1 and occasional mTORC2 inhibition 
prompted the scientist to investigate the effects of Rapamycin, mTORC1, and mTORC2 in 
tumor growth and development. 
A series of in vivo experiments have highlighted the effect of mTOR inhibition not 
only on tumor growth, but also on tumor vascularization. Temsirolimus (commercial name 
for Rapamycin) successfully inhibited tumor growth and vascularization in a xenograft 
model of Matrigel plugs containing Human Epidermal Growth factor Receptor (HER)-
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dependent breast cancer cells. mTORC1 silencing by siRNA interference confirmed the 
involvement of this signaling pathway. Similarly, Rapamycin and analogues exerted 
analogous inhibitory effects on the growth of Kaposi sarcoma and vascular tumors in in 
vivo models (146-148). Furthermore, the anti-angiogenic effect of mTOR inhibition was 
linked to inhibition of VEGF expression and translation (149-151).  
While these effects were initially attributed to specific inhibition of mTORC1, later 
studies also implicated Akt and mTORC2 to be part of anti-angiogenic response by 
Rapamycin and analogues (150,152). Development of new mTOR inhibitors that 
specifically inhibit both mTORC1 and mTORC2 underscored the anti-tumor and anti-
angiogenic potential of the mTOR signaling pathway: Dual inhibition resulted in more 
pronounced decrease in tumor growth, tumor vascularization, and VEGF production from 
tumor cells in a spontaneous pancreatic islet tumor model in comparison with Rapamycin 
alone, revealing an important role for mTORC2 in tumor growth and angiogenesis. Possibly 
the dual inhibition of the two mTOR complexes abolishes any negative feedback loop that 
would activate mTORC2 signaling (153-156).  
Besides vascular regression, targeting mTOR may also normalize aberrant tumor 
vasculature: The concept of vascular normalization aims at increasing the functionality of 
improperly formed tumor vasculature. Fokas et al. have shown that dual inhibition of 
mTOR pathway and PI3K pathway resulted in improved vascular structure and better tumor 
oxygenation, which in turn sensitizes the tumor for radiotherapy (157,158).  
In vitro experiments are expected to shed some light on the mechanism by which 
mTOR regulates tumor growth and – more interestingly for the purposes of this thesis - 
tumor vascularization. Initially it was shown that Rapamycin can inhibit the accumulation 
of HIF-1α in prostate and breast cancer cells. Decreased HIF-1α ultimately resulted in lower 
VEGFA levels in normoxic and hypoxic conditions, clearly suggesting a role for mTORC1 
in VEGFA production and stimulation of sprouting initiation (134,146,159). Recent work 
revealed that mTORC1 regulates VEGFA production in a HIF-1α-dependent but also -
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independent manner (160). HIF-1α is shown to be directly regulated by mTORC1 and 
recent data showed that Rictor specifically regulates the expression of HIF-2α and the 
stabilization of this hypoxia induced factor (161) 
The fact that mTOR inhibitors affect tumor vascularization in vivo draws attention 
to mTOR signaling in endothelial cells, since endothelial cells are the drivers of 
angiogenesis. It has been demonstrated that mTOR signaling is required for endothelial cell 
proliferation and in vitro angiogenesis. Under hypoxic conditions, which are usually found 
in tumors, both mTORC1 and mTORC2 are needed for endothelial cell proliferation (162). 
Inhibition of both complexes with Rapamycin inhibited sprouting of endothelial cells from 
rat aortic rings specifically under hypoxia (162,163). Temsirolimus not only inhibited 
endothelial cell proliferation and migration, it also decreased VEGF and PDGF secretion in 
a model of retinal vascularization (164). The functional significance of Akt/mTOR 
signaling was highlighted when inhibition of these pathways in endothelial cells decreased 
survival and proliferation of endothelial cells due to FoxO1/3a activation (165).    
In most of the above mentioned experiments Rapamycin or Rapamycin-based 
inhibitors have been used to assess the role of mTOR in angiogenesis. However, it is not 
clear to which mTOR complex the observed effects can be attributed. A few recent studies 
showed that PGE2-induced endothelial survival and migration is directly regulated by 
mTORC2 and that the PI3K/mTORC2 signaling axis is central for VEGF-mediated 
endothelial cell survival via FoxO1/3a (166,167). 
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1.7. Aims and experimental approach 
In vivo experiments with dual inhibition of mTOR complexes indirectly suggest a 
specific and distinct role for mTORC2 in tumor vascularization. However the nature of the 
existing mTOR inhibitors does not allow the discrimination between the individual 
functions of mTORC1 and mTORC2 in angiogenesis. It is evident that the specific roles of 
mTORC2 in angiogenesis are not yet defined. Specifically, the role of mTORC2 in the 
biology of the endothelium as the initiating tissue during sprouting angiogenesis remains to 
be elucidated. VEGF and FGF2, abundantly found in growing tumors are the most 
important and orchestrating growth factors in both physiologic and pathological 
angiogenesis that will be used as stimulus for angiogenesis in vivo. 
 
Aims of this thesis 
Assessment of the role of endothelial mTORC2  
 in vascular homeostasis  
 in existing vascular beds challenged by high doses of VEGF and FGF2  
 in neo-vascularization in response to a high dose of VEGF and  FGF2  
 
Experimental approach 
Ceasing mTORC2 signaling in the endothelium is induced by the deletion of Rictor, an 
mTORC2 specific accessory protein. Endothelium-specific and Tamoxifen inducible 
Rictor knockout mice were used in order to study the role of endothelial mTORC2 in 
angiogenesis in vivo. The experimental approach includes: 
 Validation and assessment of Rictor knockout in the endothelium from these 
transgene mice 
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 Monitoring and assessment of the health status of control and knockout mice during 
adolescence 
 Monitoring existing vascular beds of control and knockout mice using the dorsal 
skinfold chamber and fluorescent intravital microscopy  
 Modification of the dorsal skinfold chamber for FGF2-stimulation of the skin 
muscle vasculature and monitoring of vascular changes 
   Assessment of neo-angiogenesis in FGF2-loaded Matrigel plugs 
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2. Materials and methods 
2.1. Endothelial specific and Tamoxifen inducible Rictor
iΔec
 mouse 
Mice with floxed Rictor exons 3 and 4 (168, 169) were crossed with mice that 
express Tamoxifen (Tx)-inducible Cre-ER
T2
 recombinase under the transcriptional control 
of the endothelium-specific VE-cadherin promoter (VECad-Cre-ER
T2
) (170) (kind gift of 
Dr. Iruela-Arispe, Department of Molecular, Cell & Developmental Biology, UCLA, USA), 
both on a congenic C57Bl/6J background. Offspring were genotyped for Cre-recombinase, 
Rictor
 floxed
 and Rictor
wt
 alleles using qPCR. Briefly, DNA was isolated from ear biopsies 
and amplified by qPCR with the following primer pairs (5’-3’): Forward: GCG GTC TGG 
CAG TAA AAA CTA TC; Reverse: GTG AAA CAG CAT TGC TGT CAC TT. The mice 
were bred, housed and handled according to the local animal ethics committee (license 
77/2009 and 179/2012, Kantonales Veterinäramt Zürich).  
 
2.2. Determination of Rictor mRNA expression levels in aortic endothelium  
2.2.1. Scraping of aortic endothelium 
Rictor deletion was induced in VECad-Cre-ER
T2 +/+ 
; Rictor 
floxed/floxed
 mice at an age 
of four weeks with five consecutive intraperitoneal Tamoxifen (Tx) injections (2 mg Tx /ml 
dissolved in corn oil at a concentration of 80 mg/kg bodyweight, T5648, Sigma-Aldrich). 
Littermate control mice were injected with vehicle corn oil alone. Aortae were excised from 
2 or 6 month old Tx-injected (Rictor 
iΔec
) and control mice (Ctrl), cleaned from adhering 
tissue and opened longitudinally. Endothelial cells were carefully scraped directly in RLT 
buffer (Qiagen) and RNA was extracted using the RNAeasy micro kit (Qiagen) according 
to the recommendations of the manufacturer. Equal amounts of RNA were transcribed to 
cDNA by WT (Whole Transcript)-Ovation™ Pico RNA Amplification System (NuGEN). 
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Quantitative real-time PCR was performed using a SYBR green-based standard protocol. 
Tubulin, GAPDH, and β-actin were used as housekeeping control. The specificity of the 
primers was tested by melt curve and agarose gel analysis and sequencing. Relative 
expression levels were calculated using the comparative ΔΔCt method (171). 
2.2.2. Enzymatic digestion of aortic endothelium 
Two month old mice were sacrificed and thoracic aorta was excised and transferred 
in petri dish. A pediatric catheter was inserted in one edge of the aorta and was stabilized 
with a hemostatic clamp. The aorta was washed with ice cold PBS through the catheter. 
Then the other opening of the aorta was sealed with a hemostatic clamp. Trypsin 
0.25%/EDTA (Gibco), Collagenase D or Liberase (172) were administered in the clamped 
aorta through the catheter. Aortic walls were incubated with the enzymes for 7-10 minutes. 
After enzymatic digestion, the detached cells were flushed with Vasculife endothelial 
specific medium (Lifeline Cell technology) in a collection tube for total RNA isolation. A 
piece of the denudated aorta was kept as a negative control.  
 
2.3. Determination of Rictor mRNA expression levels in lung endothelium 
2.3.1. Magnetic Activated Cell Sorting (MACS) lung endothelial cells isolation  
Lungs were excised from 2 month old Tx-injected (Rictor 
iΔec
) and control mice 
(Ctrl), and stored in Vasculife endothelial specific media (on ice). When lungs from all 
mice were removed, samples were transferred under sterile laminar flow. Lungs were 
washed with ice cold PBS and minced with parallel scalpels and scissors. Minced lung 
tissue from every mouse was incubated in Collagenase D (1mg/ml, Roche) for 1 hour at 
37
O
C. Every 5 minutes the collagenase-lung suspension was re-suspended with a 5 or 10ml 
serological pipette. Collagenase activity was blocked with 5ml bovine serum and the cell 
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suspension was washed with MACS buffer (1% BSA in PBS). Cell suspension was passed 
through a 70μm nylon mesh. Cells that passed through the mesh were washed 2 times with 
MACS buffer and then passed through a 30µm Pre-Separation filter (MACS, Miltenyi 
Biotec). Cells were incubated with 2% mouse serum at 4
 O
C for 30 minutes. Cells were 
washed with MACS buffer and incubated 4
O
C for 30 minutes with rat anti-mouse CD31, rat 
anti-mouse CD105 (BD Pharmigen) and biotinylated Isolectin B4 (Vector laboratories). 
Cells were labeled with secondary goat anti-rat IgG microbeads (MACS, Miltenyi Biotec), 
which are magnet conjugated antibodies and magnet conjugated Streptavidin (MACS, 
Miltenyi Biotec). Cell suspension was passed through MACS magnetic LS separation 
column (MACS, Miltenyi Biotec). The positive and negative selected cells were directly 
subjected to total RNA isolation with Qiagen RNAeasy mini kit.  
Enrichment of the MACS sorted endothelial cells was achieved with the culture of 
the CD31
+
/CD105
+
/IB4
+
 positive selected cells. The positive selected population was plated 
in a 2% collagen (Carl Roth GmbH 4274.1) coated 3 cm petri dish and cells were cultured 
at 37
o
C and 5% O2 in Vasculife endothelial specific medium for 7 to 10 days until 60% 
confluence and then total RNA was extracted. 
 
2.3.2. Fluorescence Activated Cell Sorting (FACS) of lung endothelial cells  
Lungs were excised from 2 month old Tx-injected (Rictor 
iΔec
) and control mice 
(Ctrl), and stored in Vasculife endothelial specific media on ice. When lungs from all mice 
were removed, samples were transferred under sterile laminar flow. Lungs were washed 
with ice cold PBS and minced with parallel scalpels and scissors. Minced lung tissue from 
every mouse was incubated in Collagenase D (1mg/ml, Roche) for 1 hour at 37
O
C. Every 5 
minutes the collagenase-lung suspension was re-suspended with a 5 or 10ml serological 
pipette. Collagenase activity was blocked with 5ml Vasculife endothelial specific medium 
and the minced tissue was passed through a 100μm nylon mesh. Cells were washed in ice 
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cold FACS buffer (1%BSA in PBS), counted and passed through a 30μm Pre-Separation 
Filters (MACS, Miltenyi Biotec). Cell suspension was incubated with FACS buffer for 30 
minutes in ice and then incubated with rat anti-mouse APC-CD31 and rat anti-mouse PE-
Cy7-CD45 antibody (BD Pharmigen) for 30 minutes in dark. Live/dead staining with aqua 
fluorescent Live/Dead Fixable Cell Stain kit (Invitrogen) was made 30 minutes before 
FACS analysis and sorting Final samples were reconstituted in 400μL volume of FACS 
buffer and FACS sorting was conducted with FACSAria III sorter (Flow cytometry facility, 
University of Zurich, Irchel Campus). Single cells were gated and live/dead cells were 
distinguished. CD31
+
/CD45
- 
cells of the gated cell population represent the endothelial 
cells. Positive and negative populations were flushed in Vasculife endothelial medium or 
directly in RLT buffer for total RNA isolation. 
2.4. Determination of the efficiency of endothelial cell isolation and Rictor knockout 
induction efficiency 
Endothelial cell isolation was attempted with the above mentioned techniques, i.e. 
aorta scraping, aorta enzymatic digestion, lung endothelial cells isolation with MACS and 
enrichment with culturing and FACS sorting of lung endothelial cells. Total RNA isolation 
was conducted with either RNeasy-mini or RNeasy-micro kit (Qiagen) depending on the 
amount of isolated cell populations. Equal amounts of RNA were transcribed with iScript 
kit (Biorad). When the amount of total RNA that was isolated was below 20ng/μL 
transcription and cDNA amplification was conducted with WT (Whole Transcript)-
Ovation™ Pico RNA Amplification System (NuGEN). The presence of endothelial cells in 
the isolated cell populations and the efficiency of the isolation technique were assessed with 
qRT-PCR using a SYBR green-based standard protocol for CD31, Ve-Cadherin, CD45, and 
SPA when the isolation was performed from lung tissue. SMA was assessed when the 
isolation was performed from aortic tissue. Rictor deletion and Cre-ER
T2
 expression in the 
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endothelium was assessed in the same tissues with real-time PCR. All primer sequences are 
at the end of the Material and Methods section. 
2.5. Rictor KO aortic endothelial cells  
Mouse aortic endothelial cells (MAECs) were isolated from aortae of 8-10-week-
old Rictor floxed male mice as described earlier (173)
,
(163). Rictor KO cells were 
generated by adenoviral transfection of Cre-Recombinase. 8x10
5
 Rictor floxed MAECs 
were seeded on a 10 cm culture dish. The next day, the media was removed and a virus (100 
MOI) that contained either Ade-CRE-GFP (Vector Biolabs 1045) or Ade-CMV-GFP 
(Vector Biolabs 1060) was added in 3 ml of growth media to the cells. After 6 hours, the 
media was removed, replaced by 10 ml of normal growth media, and incubated at 37°C. 
Endothelial cells expressed GFP the following day. Down-regulation of Rictor and 
disruption of mTORC2 signaling was assessed by using qRT-PCR. Rictor knockout and 
control MAECS were used as control samples for the detection of Rictor qRT- PCR in the 
lung or aortic isolated endothelial cells. 
For all experiments using MAECs, cell culture dishes were coated with 0.1% 
gelatin gold (Carl Roth GmbH 4274.1) for 20 minutes at 37°C. MAECs were maintained in 
DMEM (Biochrom FG435), complemented with 10% or 1% (complete or starvation 
medium), FCS (Biochrom S0615), 1% sodium pyruvate (GIBCO 15140), 1% non-essential 
amino acids (GIBCO 11140), and 1% penicillin-streptomycin (GIBCO 15140). Stimulation 
with growth factors always included addition of heparin at a fixed ratio (1 IU heparin per 1, 
5 μg/ml GF). 
2.6. Mouse dorsal skinfold chamber and Matrigel sealing 
To study the capillary remodeling and angiogenesis in vivo we used the dorsal skin 
fold chamber as described previously (174) with a novel modification in order to deliver 
growth factors via Matrigel to the tissue. Figure 8 shows the steps for the surgical 
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implantation of the dorsal skinfold chamber. Briefly for chamber implantation, two 
symmetrical titanium frames were mounted on the dorsal skin fold of the animal. One skin 
layer as well as the underlying fat were then completely removed in a circular area of 15 
mm in diameter, and the remaining layers (consisting of striated skin muscle, subcutaneous 
tissue and skin) were covered with NaCl 0.9% and a glass cover slip incorporated into one 
of the titanium frames. The animals were allowed to recover for two days. The baseline 
vasculature was recorded with intravital microscopy (see below) and then, skin from the 
remaining layer was carefully detached from the underlying muscle and removed in a 
circular area of 7 mm in diameter from the back of the chamber. Growth factor reduced 
Matrigel (BD Biosciences) was thawed on ice and mixed with either FGF2 (1,5 mg/ml) or 
VEGF (1,5mg/ml) (R&D Systems) and Heparin (5 IU units B.Braun) or Heparin alone. The 
defect on the back of the chamber was sealed with 200μl of the Matrigel mixtures that were 
allowed to gel for 5 min, and covered with NaCl 0.9% and a glass cover slip incorporated 
into the other titanium frame. 
An alternative modification for VEGF delivery in the dorsal skin was the 
intramuscular injection of primary myoblasts isolated from C57BL/6 mice and transduced 
to express the -galactosidase marker gene (lacZ) from a retroviral promoter (175). They 
were further infected at high efficiency (176) with retroviruses carrying the cDNA for 
murine VEGF164 (176). Myoblast clones were isolated using a FacStar cell sorter (Becton 
Dickinson) and single cell isolation was confirmed visually. The stability of the VEGF 
secretion was assessed periodically by ELISA. All myoblast populations were cultured in 
5% CO2 on collagen-coated dishes as previously described (kind donation from Dr. Roberto 
Gianni Barrera, University Hospital Basel Institute for Surgical Research and Hospital 
Management Cell and Gene Therapy Group) (176). Figure 8 below all the steps of the 
surgical implantation of dorsal skinfold chamber. 
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Figure 8. Overview of the implantation of the dorsal skinfold chamber. Surgical procedure for the dorsal 
skinfold chamber implantation (A-F). The skin muscle vasculature through the observation window of the 
skinfold chamber (G). Modification of the dorsal skinfold chamber for growth factor delivery. Skin defect on 
the opposite site of the observation window sealed with Matrigel to deliver growth factors (I). 
 
2.6.1. Intravital microscopy 
Repetitive intravital microscopic analyses of skin microvasculature were carried out 
daily over a time period of 7 days. Microscopic images were taken at 8 different areas 
A B 
C D 
E F 
G I 
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within the center and the periphery of the wound. After intravenous injection of 0.2 ml 
FITC-labeled dextran (2%; MW 70000, Sigma-Aldrich, Munich, Germany) the 
microcirculation was visualized by intravital fluorescence microscopy (Leica DM/LM; 
Leica Microsystems, Wetzlar, Germany). Microscopic images were captured by a CCD 
television camera (Kappa Messtechnik, Gleichen, Germany) and recorded on video (50 Hz; 
Panasonic AG-7350-SVHS, Tokyo, Japan) for subsequent offline analysis. Using × 10 (N-
Plan × 10/0.25 LD, Leica), × 20 (HCX Apo × 20/0.50 W, Leica) objectives blood flow was 
monitored in capillaries of the superficial and deep dermal plexus of the skin muscle. The 
epi-illumination setup included a mercury lamp with a blue filter (450–490 nm/>520 nm 
excitation/emission wavelength) and a green filter (530–560 nm/>580 nm). Quantification 
of vascular parameters was done with CapImage version 8.6.3 software (Created by Dr. 
Zeintl). 
2.7. Matrigel plug assay 
The Matrigel plug assay was performed as previously described (177). In brief, 8-
week-old male C57BL/6 mice were injected subcutaneously with 0.20 ml of Matrigel 
containing 1.5μg/ml FGF2 with 1μl (5 IU) Heparin. The injected Matrigel rapidly formed a 
single, solid gel plug. After 7 days the mice were euthanized and the skin was pulled back 
to expose the Matrigel plug. The Matrigel plug was removed, photographed, fixed in 
formalin, and paraffin embedded. Hemoglobin content was roughly estimated by measuring 
the magenta channel in CMKY converted images by NIH Image J program. Sections were 
made and infiltrating ECs were identified with rabbit polyclonal anti-mouse CD-31(1:10, 
Lifespan Biosciences) immunohistochemical staining according to the manufacturer’s 
protocol. 
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2.8. Immunohistochemical staining 
On day 7 of intravital microscopy experiment was terminated and skin muscle was 
removed, washed and fixed in 2% paraphormaldehyde overnight. The next day tissue was 
paraffin-embedded and then sectioned. Similar procedures were followed for the Matrigel 
plugs after experiment termination. Capillaries and vessels were immuno-labeled with 
CD31 peroxidase staining. Briefly, sections were deparaffinized and rehydrated in xylene 
and in decreasing concentrations of ethanol. Antigen retrieval was done by boiling in 
Trisodium Citrate (Tri.Na.Citrat) (ph6.4). Tissue sections were blocked with 10% goat 
serum in 1% BSA / 0.1% TritonX-100 in PBS. Rabbit polyclonal anti-mouse CD31 
antibody (1:10) (Lifespan Biosciences) was added and detection was made with Peroxidase 
rabbit IgG Vectastain ABC kit (Vector Laboratories), following manufacturer’s 
instructions. Nuclei were stained with Hematoxylene and sections were dehydrated in 
increasing concentrations of ethanol and xylene. The cover slip was mounted with 
permanent VectaMount mounting medium (Vector Laboratories). 
Cre-ER
T2 
was visualized by immuno-fluorescent staining of Estrogen Receptor α 
(ER
T2
). Briefly, sections were deparaffinized and rehydrated in xylene and decreasing 
concentrations of isopropanol and antigen retrieval was done with boiling in Trisodium 
Citrate (Tri.Na.Citrat). (ph6.4). Tissue sections were blocked with 10% goat serum in 1% 
BSA / 0.1% TritonX-100 in PBS. Primary rabbit polyclonal anti-mouse anti-Estrogen 
Receptor α antibody (1:400/Millipore) was added and detection was made with secondary 
goat anti-rabbit Alexa-Fluo 555 (1:200/Invitrogen). Nuclei were stained with Hoechst 
33342 (1:200/Invitrogen) and the cover slip was mounted with Fluosave (Calbiochem). 
2.9 Statistical analysis 
Statistical tests were performed by using GraphPad Prism 5.04 for Windows® 
(GraphPad software, San Diego, CA, USA). We have used unpaired t-test to evaluate 
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differences between two groups. If there were more than two groups, we used one-way 
ANOVA, followed by a Bonferroni post-test. P<0.05 was considered significant. 
 
2.10. Primer list  
Gene  Forward Primer Reverse Primer 
β-actin CGT GCG TGA CAT CAA AGA GA CCC AAG AAG GAA GGC TGG A 
β-Tubulin TCA CTG TGC CTG AAC TTA CC GGA ACA TAG CCG TAA ACT GC 
CD31 AGG CTT GCA TAG AGC TCC AG TTC TTG GTT TCC AGC TAT GG 
CD45 GAA CAT GCT GCC AAT GGT TCT TGT CCC ACA TGA CTC CTT TCC 
Cre CGT ACT GAC GGT GGG AGA AT CCC GGC AAA ACA GGT AGT TA 
GAPDH AAA TGG TGA AGG TCG GTG TG- GTT GAA TTT GCC GTG AGT GG 
Rictor TGC GAT ATT GGC CAT AGT GA ACC CGG CTG CTC TTA CTT CT 
SMA GCG GCC TTT AAA CCC CTC ACC C GAG GCA GAG AAG GCT TGG TCG T- 
SPA AGG CAG ACA TCC ACA CAG CTT ACT TGA TGC CAG CAA CAA CAG T 
Ve-Cadherin GCT GAC CAG CCT CCA ACG GG TGC TCT CAA GTG AAA CCG GGC T 
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3. RESULTS 
 3. A. Endothelial specific Rictor knockout mouse: Assessment of the efficiency of 
Rictor knockout in the endothelium 
 
3. A.1. Induction of Rictor knockout in the adult mouse endothelium 
 
Investigation of the role of endothelial mTORC2 in angiogenesis in vivo was 
conducted by using an endothelial specific and inducible Rictor knockout mouse, as Rictor 
is a specific component of mTORC2. This mouse was generated by crossing a mouse with 
loxed exons 4 and 5 of the Rictor gene (168, 169) with a mouse expressing Cre-ER
T2 
under 
the transcriptional control of Ve-Cadherin promoter (170). Tamoxifen injections of Cre-
ER
T2 +/+
 mice at the age of 4 weeks allowed Cre-ER
T2 
recombinase translocation into the 
nucleus of endothelial cells and the excision of exon 4 and 5 of Rictor. As control Cre-
ER
T2+/+
 mice were injected with corn oil (170). 
  Figure 1 shows the efficiency of Rictor knockout induction in the aortic 
endothelium of adult mice (February 2011). These mice were used in this project in order to 
assess the role of endothelial mTORC2 in angiogenesis in vivo. The efficiency of Rictor 
knockout was assessed in the aortic endothelium of 28-week-old mice. Aortas of corn oil or 
Tamoxifen injected mice were removed, washed, and cut in a flap mount. The aortic 
endothelium was treated with RLT buffer for total RNA isolation and smoothly scraped 
with a scalpel.  
 
 
 
 
 
 
 
Figure 1: mRNA levels of Rictor and Cre-ER
T2
 recombinase in scraped aortic endothelium. Rictor mRNA levels show 
almost complete ablation of Rictor expression in Tamoxifen-treated Rictor
iΔec 
mice (Control n=3/Rictor
iΔec 
n=2). Cre-ER
T2
 was 
expressed in Cre+ animals and was absent in Cre- animals. Brown fat from a constitutive Rictor knockout model in the adipose 
tissue was used as a control for Rictor knockout efficiency and Cre expression. 
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Detection of Rictor mRNA levels of scraped endothelium of control versus 
Rictor
iΔec 
mice showed complete depletion of Rictor expression and high efficiency of 
Rictor knockout induction with this Tamoxifen injection regimen (Figure 1). Adipose 
tissue from an adipose specific and constitutive Rictor knockout mouse was used as a 
control for Cre-mediated expression and Rictor deletion (179). The adipose tissue of these 
mice exhibited an established significant reduction of Rictor mRNA expression levels of 
about 50% (Figure 1). The levels of Cre-ER
T2
 recombinase mRNA varied in different Cre
+ 
animals and were absent in Cre
-
 adipose specific Rictor knockout animals (Figure 1). 
The presence of endothelial cells in the scraped tissue was confirmed by Real-Time 
PCR. CD31 and Ve-Cadherin were used as markers for endothelial cells while CD45 as a 
marker for blood cells (178) and Smooth Muscle Actin (SMA) as a marker for smooth 
muscle cells. Figure 2 shows the mRNA expression profile of the scraped aortic 
endothelium.  
High levels of CD31 mRNA confirmed endothelial cell abundance in the scraped 
tissues. Ve-Cadherin showed variable mRNA expression levels among the samples. CD45 
mRNA was detected in the scraped tissue of the corn oil injected animals.  CD45m RNA 
represent hematological cells that also co-express CD31 and these cells can contribute to 
some extend in the CD31 mRNA levels observed (178). However, smooth muscle actin 
mRNA levels were low in the scraped endothelium of both animal groups compared to the 
levels from the whole aorta (Figure 2). 
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Figure 2: mRNA levels of endothelial, hematologic and smooth muscle markers of scraped aortic endothelium and full 
aorta. CD31 and Ve-Cadherin mRNA levels are used as endothelial positive markers. CD45 and SMA are used as 
hematological cell and smooth muscle cells markers respectively. The scraped endothelium of Control (Cre+/+, Tamoxifen -) 
and RictoriΔec (Cre+/+, Tamoxifen+) showed abundant presence of CD31 positive cells and presence of Ve-Cadherin mRNA. 
CD45 mRNA was not equally distributed between the sample and the smooth muscle cells were not present in the scraped 
endothelium. (Control n=3/RictoriΔec n=2) 
 
 
 
3. A.2. Efficiency of Rictor knockout induction in endothelial cells in aorta and lungs  
 
At  the end of the second year of the project (September 2013) and after acquiring 
the in vivo data presented in this thesis (Results Part B) the question about the Rictor 
knockout induction efficiency in tissues that are subjects of investigation (muscle, retina, 
and tumors) was raised.  
The designed experimental approach was based on optimization of endothelial cell 
isolation with Magnetic Activated Cell Sorting (MACS) from the lungs, the most 
vascularized tissue in the body (180). After the optimization of the technique, endothelial 
cells from skin muscle, retina and melanoma tumors would be isolated in order to assess the 
efficiency of Rictor knockout. The efficiency of Rictor knockout in the aortic endothelial 
lining as observed in the beginning of the project, would be considered as an internal 
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control for the efficiency of Rictor knockout induction in the lung endothelial cells and the 
mRNA levels of aortic endothelial Rictor would be assessed side by side with mRNA 
arriving from lung endothelial cells or cells from other tissues. 
Thoracic aorta and lungs from 3 control and 3 Rictor
 iΔec 
mice were dissected in 
order to isolate the aortic endothelial lining and the lung endothelial cells. The lungs of the 
3 control and 3 Rictor
 iΔec 
mice were pooled together in order to increase the number of 
endothelial cells that would arrive from the MACS isolation. The scraping of aortic 
endothelium has been previously conducted; one aorta can provide enough endothelial 
material in order to conduct gene expression analysis (Figure 1). 
3. A.2.1. Rictor mRNA quantification and cell marker profiling of aortic endothelial 
lining 
 
The presence of endothelial cells in the scraped lining was assessed as previously 
described in Figure 1. Established cultures from our laboratory, of control and Rictor KO 
MAECS were used as samples of pure endothelial cells and as a control of Rictor mRNA 
depletion.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: mRNA levels of endothelial, hematologic and smooth muscle cell markers in cultured 
endothelial cells and scraped aortic endothelium. Each column of the aortic endothelium represents one 
animal. (A) Expression levels of Ve-Cadherin and CD31 mRNA as endothelial specific markers and CD45 and 
SMA mRNA levels as controls for the presence of blood cells and smooth muscle cells respectively. (B) 
Variable Rictor mRNA levels showing no induction of the Rictor knockout in scraped aortic endothelium (n=3). 
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The scraped endothelial lining was positive for CD31 mRNA. However Ve-
Cadherin was very low expressed. The cultured MAECs show a reverse mRNA profile of 
CD31 and Ve-Cadherin (Figure 3A). There is a low presence of CD45 positive blood cells 
and a sporadic presence of smooth muscle cells. (Figure3A). In the scraped endothelium of 
the three individual Rictor
iΔec 
animals the Rictor mRNA levels showed that there is no 
knockout induction and that the levels of Rictor mRNA in the Rictor
iΔec 
animals were even 
higher than in control mice (Figure 3B). Based on the Rictor mRNA levels, the fact that 
Ve-Cadherin mRNA was not detectable in the scraped endothelium and the results from the 
respective experiment on 2011 (Figures 1-2) doubts concerning the efficacy of Rictor 
knockout induction and the and the efficiency of the aortic scraping as a technique was 
raised.  
 
3. A.2.2. Rictor mRNA quantification and cell marker profiling of MACS sorted lung 
endothelial cells 
 
The lungs of the above three control and Rictor
iΔec 
mice were subjected to 
collagenase digestion and endothelial cells were sorted with MACS based on the presence 
of CD31, CD105 cell surface markers and Isolectin B4, which specifically binds to 
endothelial cells (181). Total RNA was isolated from the CD31
+
/CD105
+
/IB4
+
 cell 
suspension and from the flow-through of the magnetic separation that should contain all the 
non-endothelial lung cells.  
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Figure 4 Quantification of Rictor mRNA of directly MACS-sorted murine lung endothelial cells. Lungs 
from three mice per group were pooled together. Every sample represents three mice. (A) mRNA levels of 
endothelial CD31 was equal in two animal groups. mRNA of Ve-Cadherin was not present. High rate of CD45 
positive cells was observed. Lung epithelial cells were removed during the isolation process since SPA mRNA 
was absent the sorted ECs sample but highly present in the flow-through. (B) Rictor
iΔec 
mice show reduced mRNA 
levels, but Rictor mRNA levels from the aortic endothelium of the same animals (Figure 3) show no Rictor 
knockout induction (n=3). 
 
The positively CD31
+
/CD105
+
/IB4
+
 selected cells present no mRNA of Ve-
Cadherin and the amount of CD31 mRNA was equal in both control and Rictor
iΔec 
mice. On 
the other hand there is a very high presence of CD45
+
 blood cells. The efficiency of the 
magnetic separation was adequate in order to discard the lung epithelium from the sorted 
cells since SPA mRNA was not detected (Figure 4A). The levels of Rictor mRNA in the 
CD31
+
/CD105
+
/IB4
+
 samples arriving from the 3 Rictor
iΔec 
mice were about 50% lower 
than in the samples arriving from the control mice. The negative selected cells also present 
similar levels of CD31 mRNA and the same trend of Rictor mRNA.  
In combination with the results from the aortic endothelium scraping the data 
suggest that either the techniques used are not adequate to demonstrate the efficiency or 
Rictor knockout induction, or that the knockout of Rictor in the endothelium is not induced 
(Figure 3/Figure 4). 
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3. A.3. Isolation of pure endothelial cell populations from aorta and lungs: 
optimization and gene expression analysis. 
 
As the above data could not proof the induction of Rictor knockout in the aortic 
endothelium, we invested on other techniques for isolation of enriched and pure endothelial 
cell populations for gene expression analysis to monitor Rictor knockout efficiency. 
Optimization of aortic endothelial cells isolation was attempted with enzymatic digestion of 
the aortic wall. Isolation of lung endothelial cells was approached simultaneously with two 
different techniques: MACS sorting and culturing the isolated cells and FACS sorting. The 
first part of the following results describes the isolation of aortic endothelial cells with 
enzymatic digestion of the aortic wall. The second part presents the MACS isolation and 
optimization and FACS sorting of lung endothelial cells. 
  
 
3. A.3.1. Rictor mRNA quantification and cell marker profiling of enzymatically 
digested aortic lining 
  
 Techniques of enzymatic digestion of the aortic endothelium to isolate pure 
populations of aortic endothelial cells were used. Digestion of the endothelium was 
attempted with Trypsin, Collagenase and Liberase. 
 
3. A. 3.1.1. Enzymatic digestion by trypsin 
 
The aortas of two control and one Rictor
 iΔec 
mice were removed from the thorax 
and cannulated ex vivo from one side and clamped from the other. Trypsin 0,25%+EDTA 
was flushed through the cannula in the aorta and the enzyme was allowed to detach 
endothelial cells from the aortic wall for 7 minutes. The cells were flushed in a tube with 
endothelial specific medium and were subjected to total RNA isolation. The denudated 
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piece of aorta was kept and RNA was isolated from them as a negative control of the 
isolated endothelium.  
As shown in Figure 5A there is no Ve-Cadherin mRNA and the levels of CD31 
mRNA were very variable from high in the isolated aortic cell suspension to undetectable. 
The mRNA levels of CD45 follow a similar trend with CD31 mRNA (Figure 5A). 
 
 
 
 
Figure 5: mRNA levels of endothelial, hematologic, and smooth muscle markers and Rictor in trypsin 
digested aortic endothelium lining. (A) mRNA levels of CD31 and Ve-Cadherin serve as endothelial cell 
marker while CD45 and SMA are indicators of the presence of blood cells and smooth muscle cells from the 
aorta respectively. Pieces of denudated aortas were used for negative controls of endothelial cells and positive 
controls for smooth muscle cells. (B) Rictor mRNA levels are lower in the digested endothelial lining but the 
denudated aorta also present very low levels of Rictor expression (Control n=2, RictoriΔec n=1). 
 
 
The reduced levels of Rictor mRNA of the Rictor
iΔec 
animal cannot be 
representative of the efficiency of the induction of the knockout due to the questionable 
amount of endothelial cells that were isolated on one hand. On the other hand the denudated 
aorta of the Rictor
iΔec 
animal presents equally low levels of Rictor mRNA (Figure 5B). The 
denudated aorta of RictoriΔec mice consists of cells that express normally Rictor, so it is not 
expected to present so low levels of Rictor mRNA.  
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3. A. 3.1.2. Enzymatic digestion by Collagenase and Liberase 
 
A variation of the enzymatic digestion of the aortic endothelium with trypsin was 
followed using enzymes with higher enzymatic activity. Collagenase 1% and Liberase 1% 
(172) were used to detach the endothelial cells from the aortic wall. The same protocol as 
for the trypsin digestion was followed and cells were collected for total RNA isolation. 
Collagenase digestion resulted in similar findings with trypsin (Figures 5/6). CD31, 
CD 45 and Rictor mRNA follow the same expression trend in the Rictor
iΔec 
mice, showing 
higher levels of expression than digested aortic tissue of control animals. VE-Cadherin and 
SMA mRNA were completely absent (Figure 6A). The Rictor mRNA levels were vice 
versa from the expected results with, control animals presenting lower lever of Rictor 
expression than the Rictor
iΔec 
mice. 
Liberase enzymatic digestion detached endothelial cells from the aorta that were 
positive for Ve-cadherin and CD31 mRNA. However there were smooth muscle cells and 
some CD45 positive blood cells in the digested aortic cell suspension. Thus Liberase also 
removed part of smooth muscle cells.  
Both techniques show weakness in isolating aortic endothelial cells and more 
optimization would be necessary to stabilize the yield of isolated endothelial cells. Thus, we 
aimed for another technique to define us if knockout of Rictor occurred or not. 
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Figure 6: mRNA levels of endothelial, hematologic and smooth muscle markers in enzymatically treated aortic 
endothelial lining. (A) mRNA levels of the endothelial markers CD31 and Ve-Cadherin show variable amount 
of endothelial cells from the Collagenase aortic wall. There are also variable but high amounts of CD45 mRNA. 
Liberace treatment detached more endothelial cells but also hematological cells and smooth muscle cells were 
present in the sample. (B) mRNA levels of Rictor show no induction of knockout in Rictor iΔec animals (Control 
n=2, RictoriΔec n=1). 
 
 
 
3. A.3.2. MACS endothelial cell isolation: Enrichment and purification of lung 
endothelial cell population and gene expression analysis. 
  
The MACS isolation of lung endothelial cells is an adequate technique to remove 
the lung epithelial cells, but it was evident that it could not separate CD45 positive blood 
cells from the endothelial population (Figure 4). MACS sorted cells were plated and the 
non-adherent cells were washed away the following day. The attached endothelial cells 
were cultured until the desirable amount.  The following day microscopic observation of the 
petri dish showed that 10-30 cells were attached. The cells were cultured with growth factor 
enriched endothelial specific media under moderate hypoxia (5% O2). During 7 days of 
culturing, the cells proliferated, exhibited an endothelial phenotype with typical philopodia, 
and formed monolayers with endothelial cobblestone morphology at confluence. When a 3 
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cm dish was about 60% confluent with endothelial cells, total RNA was extracted and the 
purity of the growing endothelial cells was assessed with real time PCR. The expression 
levels of the endothelial markers were compared with directly sorted cells and their flow 
through (Figure 7). 
       
 
 
 
 
Figure 7: Enrichment of the endothelial cell population by plating CD31/CD105/IB4 positive selected cells 
with MACS sorting. Each sample represents cells from one animal. mRNA levels of endothelial markers show 
reversed expression profile in cultured CD31/CD105/IB4 positive selected cells after MACS sorting in relation 
to MACS sorted/non cultured CD31/CD105/IB4 positive population. Blood cells and lung epithelial cells are 
cleared from the MACS positive selected cells. The cultured population represents endothelial cells as seen also 
microscopically. 
 
 
 The CD31
+
/CD105
+
/IB4
+ 
sorted cells after culturing showed Ve-Cadherin and 
CD31 expression. These data are similar with expression levels of established cultured 
MAECs that are isolated and used in our laboratory (Figure 3). Directly sorted 
CD31
+
/CD105
+
/IB4
+
 cells and sorted/plated CD31
+
/CD105
+
/IB4
+
 cells show a reverse 
pattern of Ve-Cadherin and CD31 mRNA expression. The phenotype of these cultured cells 
under the microscope and the levels of mRNA of all the examined markers suggest that are 
pure endothelial cells in abundance. 
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3. A.3.2.1. Rictor mRNA quantification and cell marker profiling of MACS-sorted 
murine lung endothelial cells after in vitro culture 
 
Lungs were removed from 2 control and 2 Rictor
iΔec 
mice. Lungs were 
enzymatically digested and the MACS sorted CD31
+
/CD105
+
/IB4
+ 
fraction was plated 
separately for each individual mouse. Cells presented typical endothelial philopodia and 
created cobblestone monolayers. After 7 days of culturing total RNA was isolated. 
 
 
 
Figure 8: Enrichment and purification of MACS sorted endothelial cells and quantification of Rictor 
mRNA levels. Each sample represents one animal. (A) In vitro culture of MACS sorted CD31/CD105/IB4 
positive cells resulted into a pure CD31 and Ve-Cadherin positive endothelial cell population. Hematological 
cells (CD45) and lung epithelial cells (SPA) are absent in the sorted endothelial cells. (B) mRNA levels of 
Rictor in MACS sorted, cultured endothelial cells show no induction of Rictor knockout in lung endothelial 
cells. Constitutive Rictor knockout adipocytes were used as an internal control. Rictor knockout adipocytes have 
an established reduction in Rictor mRNA of 50-60%. 
 
 
 
Even though the population of endothelial cells was adequately pure there were no 
significant differences in Rictor mRNA levels between control and Rictor
iΔec 
mice (Figure 
8). Control and Rictor knockout samples from an established constitutive adipose specific 
Rictor knockout mouse were used as internal control for the experiment (179). The result of 
this experiment showed that Cre-ER
T2
 recombinase did not excise the exons 4 and 5 of 
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Rictor in Rictor
iΔec 
mice and that the gene is actively transcribed as in the control animal 
group. 
 
3. A.3.3. FACS sorting of lung microvascular endothelial cell 
While the process for optimizing the isolation of the CD31
+
/CD105
+
/IB4
+ 
endothelial cells with MACS sorting, an effort to acquire pure endothelial cell populations 
from lungs was attempted also with FACS sorting. Due to the importance of these 
experiments, which would indicate the current situation of the efficiency of Rictor knockout 
induction in vivo, the optimization of the MACS and FACS sorting was conducted 
simultaneously and the results from both techniques arrived within the same week. 
 FACS sorting of endothelial lung cells was designed to target endothelial cells 
which are CD31
+
/CD45
-
. This combination was designed in order to exclude blood cells 
that express CD31. The initial step in the sorting was to distinguish dead and live cells 
(Gate P1) and exclude the debris of the sample (Gate P2). Single cells were distinguished 
from multicellular clusters (Gate P3). CD31
+
/CD45
-
 positive endothelial cells were selected 
(Gate P4) against the red blood cells (Gate P5) and CD45
+
/CD31
- 
hematological cells (Gate 
P6) (Figure 9). 
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Figure 9: Isolation of lung endothelial cell with FACS sorting. Representative FACS sorting analysis of one 
control mouse. Gate P1 represents all the live cells after lung collagenase digestion and FACS antibody staining 
protocol. The aqua L-D negative cells are selected for further analysis and sorting. Gate P2 distinguishes 
between the cells and the debris that in the cell suspension. Gate P3 selects all the live single cells. All the 
duplets or bigger cell clusters are negative selected. Gate P4 represent the CD31 +/CD45- endothelial cells. Gate 
P5 represents the erythrocytes and gate P6 contained C31-/CD45+ blood cells. 
 
 
A pure CD31
+
/CD45
- 
population that corresponds to endothelial cells and which 
was about 2% of the total lung cells population was isolated. Cells were flushed directly to 
RLT buffer for total RNA isolation, transcription and Real-time PCR. 
 
3. A.3.1. Rictor mRNA quantification and cell marker profiling of directly FACS-
sorted murine lung endothelial cells 
 
Two control and two Rictor
iΔec 
mice were used for FACS sorting of lung endothelial 
cells. As observed previously with the MACS endothelial cell sorting of directly isolated 
endothelial cells, they present very low or even undetectable Ve-Cadherin mRNA while 
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CD31 mRNA is present. Purity of the population was confirmed by the absence of CD45 
and SPA mRNAs in the samples (Figure 10). 
 
 
 
 
Figure 10. mRNA quantification of FACS sorted endothelial cells for endothelial specific markers, lung 
and blood cells and Rictor. Each sample represents one animal. (A) mRNA levels of CD31 and CD45 
indicated the good technical quality of the FACS sorting CD31 +/CD45- endothelial cells. There are variable 
levels of CD31 mRNA in the sorted endothelial population and Ve-Cadherin is mostly low expressed as 
observed in MACS directly sorted cells. Blood cells and lung epithelial cells are negatively selected. (B) Rictor 
mRNA levels do not indicate that the induction of Rictor knockout took place in the endothelium of RictoriΔec 
animals.  
 
 
The result of MACS sorted/cultured endothelial cells was confirmed. No evident 
and significant differences were detected on Rictor mRNA between the two animal groups 
(Figure 10).  
In summary, all the isolation techniques employed and the gene analysis of the 
isolated cells point to the conclusion that exons 4 and 5 of Rictor are not excised anymore 
and the gene encoding Rictor is transcribed normally. 
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3. A.4. Cre-ER
T2
 expression levels in MACS and FACS-sorted lung endothelial cells 
 
The excision of exons 4 and 5 of Rictor is mediated by Cre-ER
T2
 recombinase, 
which is expressed in the endothelial cells. The above experiments showed that the Cre-
ER
T2
 –mediated Rictor excision is not occurring. Thus, we investigated the expression 
pattern of Cre-ER
T2
 in the MACS-sorted isolated endothelial cells. Cre-ER
T2
 recombinase is 
under the transcriptional control of an inserted VE-Cadherin promoter. The endogenous Ve-
Cadherin promoter is shown to normally transcribe Ve-Cadherin in these cells (Figure 8). 
The levels of Cre-ER
T2
 mRNA were assessed in cultured MACS-isolated endothelial cells. 
 
                        
                         
Figure 11. Quantification of Cre recombinase mRNA in cultured,-MACS sorted endothelial cells. The 
endothelial cells were sorted from mice positive-homozygous for Cre. These cells show no expression of Cre-
ERT2 recombinase. Brown fat from a constitutively Cre expressing mouse was used as a control. Adipose 
specific Rictor knockout, heterozygous mice for Cre display very high amounts of Cre mRNA while the control 
mice for brown fat Rictor knockout mice exhibit no Cre expression. 
 
 
As shown in Figure 11 the MACS sorted endothelial cells do not transcribe Cre-
ER
T2
. Cre-ER
T2
 mRNA was also absent from FACS directly sorted endothelial cells. Brown 
fat from constitutive adipose Rictor knockout mice was used as a control to for positive Cre 
expression (179). These data suggest that the inserted Ve-Cadherin promoter is not driving 
expression of the Cre transgene (Figure 7). 
 
 
0
1 0 0 0
2 0 0 0
3 0 0 0 Brown Fat MACS Sorted ECs 
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3. B. Role of endothelial mTORC2 in angiogenesis in vivo 
 
The assessment of the role of endothelial mTORC2 in angiogenesis in vivo was 
conducted in endothelial specific and inducible Rictor knockout mice. The efficiency of 
Rictor knockout induction, as described in figure 1 (February 2011) and the 
immunohistological staining of Cre-ER
T2
 in the tissue from these mice (Figure 28, data 
shown below) suggest that the animals included in the present study were knockout for 
Rictor and expressing Cre-ER
T2
 recombinase in the endothelium. The following 
experiments presented in this thesis were conducted with the functioning transgene animals 
and the significant differences that were observed between control and Rictor
iΔec
 animals 
enforce this statement.  
 
 
3. B.1. Deletion of Rictor in the endothelium does not affect weight gain and 
hematological profile of Rictor
iΔec
 animals 
 
After demonstrating the induction of Rictor knockout in the endothelium in 
February 2011 (Figure 1) the first study we followed was a weight gain and health status of 
male and female mice up to an age of 28 weeks. No significant differences in body weight 
or lethality were observed between control and Rictor
iΔec
 mice in both genders after 
monitoring for six months (n=10) (Figure 12). As VE-Cadherin-promoted Cre-
recombination may also affect hematopoietic development (182) we assessed hematological 
profiles in 8 weeks old control and Rictor
iΔec
 mice and found similar physiological values in 
both groups that were in the range of healthy C57/Bl6 mice (Figure 13)  
These experiments indicate that ablation of endothelial Rictor does not cause 
obvious general health problems as supported by normal weight gain, viability and 
hematological profiles. 
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Figure 12: Rictor
iΔec 
induction does not affect weight gain. Cre-ER
T2+/+
 mice were injected with Tamoxifen and corn oil 
respectively. Weight gain was normal for male and female for both control and Tamoxifen injected mice after 27 weeks of 
monitoring (n=10). 
 
 
 
                        
 
Figure 13: Endothelial Rictor knockout does not affect hematological profile. Hematological profile (Count of leukocytes, 
neutrophils, lymphocytes, monocytes and eosinophils) was assessed on 10-week-old corn oil and Tamoxifen injected male 
Cre
+/+
/Rictor 
lox/lox
 mice. Line between bars indicates normal range of parameters for C57/Bl6 mice (Control n=3/Rictor
iΔec 
n=7). 
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3. B.2. Assessment of the role of endothelial mTORC2 in angiogenesis with intravital 
microscopy 
 
One of the main goals of this project was the assessment of the potential 
microscopic alterations of capillary morphology in the skin muscle vasculature in the 
absence of endothelial Rictor and observation of the angiogenic capacity of Rictor
iΔec 
mice 
during VEGF and FGF2 stimulation of the skin vasculature. To do so, a dorsal skinfold 
chamber was surgically mounted into 8-week-old control and Rictor
iΔec 
mice and the 
existing vascular bed was observed by intravital fluorescent microscopy.  
 
 
3. B.2.1. Induction of Rictor knockout in the endothelium does not affect the 
homeostasis of developed vasculatures 
 
The skin muscle vasculature was observed three days after the implantation of the 
skinfold chamber (observation day 0, baseline). The capillary bed showed no apparent 
differences in control and Rictor
iΔec 
mice (Figure 14A). In both experimental groups the 
wound bed consisting of the panniculus carnosus with its capillary structures organized in 
typical parallel orientation and the subcutaneous layer with draining arterioles and venules 
exhibited the typical perfusion pattern as observed in previous studies of the dorsal skinfold 
chamber (174). Quantification of vascular parameters such as capillary number, capillary 
diameter, and number of branching points confirmed the similarity of the vasculature of the 
two animal groups (Figure 14B).  
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Figure 14: Endothelial Rictor knockout does not affect already developed skin muscle vasculature: 
Stacked frames of representative videos of the capillary vasculature recorded through the dorsal skinfold chamber by intravital 
fluorescence microscopy. (A) The baseline vasculature for both animal groups is identical 3 days after the implantation of the 
dorsal skinfold chamber. (B) Quantification of vascular density (Capillary and branching point number) and capillary diameter 
show that the baseline vasculature of control and Rictor
iΔec 
are identical. 
 
 
 
3. B.2.2. Endothelial Rictor knockout does not affect the response of the skin muscle 
vasculature in dorsal skinfold chamber implantation 
 
The dorsal skin fold chamber was modified by additionally removing cutis and 
subcutis on the opposite side of the observation window. This defect was sealed by growth 
factor-reduced Matrigel. The response of the vasculature into the dorsal skinfold chamber 
implantation and the presence of Matrigel on the skin defect was assessed on a daily basis 
by intravital fluorescent microscopy up to 7 days after Matrigel sealing. Both animal groups 
exhibited similar baseline vasculature architecture. Three days later, both animal groups 
showed similar response to the chamber implantation by increasing the capillary diameter. 
In the bigger arterioles and venules local vessel wall enlargements were observed (Figure 
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15A). After seven days of observation both Rictor
iΔec 
and control animals showed similar 
patterns of vascular remodeling in the skin muscle wound bed. 
 
Figure 15: Control and Rictor
 iΔec 
mice respond similarly to the dorsal skinfold chamber implantation: 
Stacked frames of representative videos of the capillary vasculature recorded through the dorsal skinfold chamber by intravital 
fluorescence microscopy are shown. (A) Skin muscle capillary structure from day 0 (baseline, 10x and 20X magnification), 
day 3 (after wound sealing with heparin‐loaded Matrigel, 20x magnification) and day 7 (20x magnification) in control (left 
micrographs) and Rictor
 iΔec 
mice (right micrographs). (B) Quantification (lower graphs) of capillary diameter demonstrates 
increase in capillary diameters with no significant differences in both animal groups. Similarly, no significant changes are 
detected in capillary number and number of branching point between control and Rictor
 iΔec 
mice (Control n=4/Rictor
iΔec 
n=4) 
 
 
A 
B 
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The quantification of vascular parameters (Figure 15B) demonstrated an increase 
in capillary diameters, but not an increase in microvessel densities (segments between 
branching points) or branching points (n=4). Of note, the changes in capillary diameters 
were mainly due to remodeling of larger sized capillaries that were connected with draining 
arterioles and venules. Importantly, dermal microvasculature responded similarly to the 
wound, the chamber implantation, and Matrigel sealing in control and Rictor
iΔec 
mice. 
During the seven day period of monitoring vascular changes we observed an inflammatory 
response likely caused by the presence of an open wound on the skin. In some animal the 
inflammatory response was obvious macroscopically by the presence of edema and fluid in 
the area of the chamber and in some cases there was accumulation of mucous material in 
the wound. However, the similar responses of vascular beds in control and Rictor
iΔec 
mice in 
the dorsal skinfold implantation provided an appropriate baseline for further studies. 
 
3. B.2.3. Assessment of the role of endothelial mTORC2 in VEGF induced 
angiogenesis  
 
 VEGF is considered one the key growth factors implicated in sprouting 
angiogenesis. It exerts its functions on endothelial cells, stimulating endothelial cell fate 
determination pathways and sprout formation (17). The investigation of the role of VEGF in 
relation to endothelial mTORC2 in angiogenesis was conducted with intravital microscopy 
of modified dorsal skinfold chamber for VEGF delivery through Matrigel. The skin muscle 
vasculature was stimulated with a high dose of VEGF (1.5μg/ml) and the vasculature was 
observed for 7 consequent days. The results of the intravital microscopy are shown in 
Figure 16A. 
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Figure 16: Control and Rictor iΔec mice response upon high dose of VEGF stimulation. 
Stacked frames of representative videos of the capillary vasculature recorded through the dorsal skinfold chamber by intravital 
fluorescence microscopy are shown. (A) Skin muscle capillary structure from day 0 (baseline, 20x magnification), day 3 (after 
wound sealing with heparin‐VEGF loaded Matrigel, 20x magnification) and day 7 (20x magnification) in control and Rictor 
iΔec mice. (B) Quantification of capillary diameter demonstrates increase in capillary diameters with no significant differences 
in both groups. Similarly, no significant changes are detected in capillary number and number of branching points between 
control and Rictor iΔec mice (n=3). 
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Both control and Rictor
 iΔec
 animals presented almost identical baseline vasculature 
as that already observed in the previous intravital microscopy experiments. 3 days after high 
dose VEGF stimulation both animal groups present almost equally dilated capillaries and 
retained their parallel orientation. No significant differences were observed even after 7 
days of continuous VEGF stimulation, with both animal groups presenting dilated 
capillaries and some extent of vascular remodeling. The appearance of the VEGF 
stimulated vasculature was similar to vasculature that was examined for the effect of the 
chamber implantation itself (Figure 15). Quantification of the microvascular density and 
capillary diameter confirmed the microscopic observations, i.e. no significant differences 
between the two animal groups and similar behavior as an un-stimulated vasculature 
(Figure 16B).  
  
3. B.2.3.1. Matrigel-mediated VEGF delivery: The role of heparin 
 
Due to the therapeutic importance VEGF its delivery in in vivo systems has been 
intensively studied. This growth factor in its free form has a half-life of 90 minutes (11) and 
it needs heparin and a scaffold mimicking the extracellular matrix to exert it biological 
function (10). Heparin is a glycosaminoglycan that naturally binds to growth factors like 
VEGF and FGF, stabilizing them, increasing their half-life and their bioavailability in in 
vivo delivery systems. FGF2 is known to be used in a mixture with heparin and scaffold 
material like Matrigel and hydrogels (75). The intravital microscopy of VEGF challenged 
vasculature showed no difference between the two animal groups. In order to exclude 
insufficient delivery of VEGF into the vasculature, we increased the amount of heparin into 
the VEGF-Matrigel mixture to optimize the half-life and the bioavailability of VEGF. 
A dose response experiment was set up with 10 fold higher heparin concentration 
than the initially used in the VEGF-Matrigel mixture. The skin muscle vasculature was 
stimulated with these mixtures and intravital microscopy was conducted. The skin muscle 
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vasculature of both control and Rictor
 iΔec 
mice exhibited similar behavior when stimulated 
with VEGF+10X heparin. Both animal groups resulted after 7 days of stimulation with 
dilated capillaries without losing their parallel orientation and the vasculature retained its 
initial architecture and basic structure (Figure 17). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: High doses of heparin do not influence the stimulatory effect of VEGF. 
Stacked frames of representative videos of the capillary vasculature recorded through the dorsal skinfold 
chamber by intravital fluorescence microscopy are shown. Control and Rictor
 iΔec 
mice respond similarly in low 
and high doses of heparin (low: Fig.15). The high amount of heparin does not change the effect of VEGF. Rictor
 
iΔec
 on day 3 visibility was not appropriate to produce a stacked image (video available). 
 
 
There are data supporting the fact that heparin has a vasodilating effect on blood 
vessels (183). In the experiments for VEGF delivery in the skin muscle vasculature through 
Matrigel seal, high doses of heparin were used and significant capillary diameter increase 
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was observed. To exclude the effect of heparin in the diameter increase that was observed, 
the skin muscle vasculature of both animal groups was stimulated with 10 fold higher 
heparin concentration through Matrigel seal. After 7 days of high dose of heparin 
stimulation the capillaries of the skin muscle vasculature presented increased capillary 
diameter in both animal groups and in comparable levels to when stimulated with 
VEGF+10X heparin (Figure 18). This experiment suggests that there is inefficient 
stimulation of VEGF through Matrigel in the dorsal skinfold chamber and the observed 
dilation is caused by high amount of heparin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: High dose of heparin acts as a vasodilator in the skin muscle vasculature. Intravital microscopy 
shows high doses of heparin increasing the capillary diameter in both animal groups. 
 
 
3. B.2.3.2. Intramuscular injection of VEGF expressing myoblasts for VEGF delivery 
in the skin muscle 
 
An alternative approach for VEGF delivery into the skin muscle vasculature was 
attempted by injecting modified murine VEGF expressing myoblasts. Primary myoblasts 
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isolated from C57BL/6 mice and transduced to express the -galactosidase marker gene 
(lacZ) from a retroviral promoter (175) were further infected at high efficiency (176) with 
retroviruses carrying the cDNA for murine VEGF164 (184). An intramuscular injection of 
VEGF expressing myoblasts was made on the dorsal skin after the skinfold chamber was 
implanted and vasculature was monitored with intravital microscopy. Only one control 
animal was used as a pilot experiment in order to assess if this approach is technically 
possible (Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Injection of murine VEGF secreting myoblast induces exaggerated capillary diameter and 
severe inflammation. Pilot experiment of one control animal. Intravital microscopy of the intramuscular 
injection area and the surrounding area. Microscopy was possible until day 3. Extensive inflammation 
influences visibility after this time frame. 
 
 
3 days post injection the myoblasts were visualized due to their red fluorescent 
color. The capillaries were visualized with FITC dextran, so there was no overlap between 
the signals. The myoblasts were not rejected at this time point by the immune system of the 
mouse. In the injection area an exaggerated angiogenic reaction was observed with extreme 
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capillary and vessel dilation with many and big protuberances in the capillary and vessel 
walls. The area around the injection was characterized by capillaries with increased 
diameter. However from day 4 and on microscopy of the area was not possible due to 
extensive edema and mucus (Figure 19). 
The observations on day 3 suggest that myoblast can deliver VEGF and that the 
secreted growth factor stimulates angiogenesis. However the inflammation due to the 
presence of the myoblast and the trauma from the intramuscular injection is considerable 
and substantial. Furthermore visibility during microscopy was restricted after day 3. Indeed, 
myoblasts are derived from a BL6N sub-strain which may have a different immunogenic 
background than our mice with a BL6J background. Therefore, we did not further consider 
the application of this type of VEGF delivery. 
 
3. B.2.4. Matrigel-mediated FGF2 stimulation of the skin muscle vasculature: 
Rictor
iΔec
 animals present different remodeling patterns  
  
FGF2 is a potent angiogenic factor with an established function in vascular 
development and angiogenesis. This growth factor affects multiple cell types related to 
angiogenesis and it exerts its angiogenic function in endothelial cells by regulating VEGF2 
and VEGFR2 expression among others (80). Since FGF2 is acting up-stream from VEGF 
and it is known to orchestrate the angiogenic response (80) we then proceeded to assess the 
potential role of endothelial mTORC2 in vascular morphologic changes in response to 
FGF2.  
The skin muscle vasculature was stimulated with a high dose of FGF2 (1.5 μg/ml) 
that was delivered as already described with Matrigel. Morphologic changes were 
monitored with intravital fluorescent microscopy. The effective pro-angiogenic 
concentration of FGF2 was determined in pilot experiments using Matrigel plugs injected 
s.c. at the ventral flank of the mice (Data not shown).  
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Intravital recordings through the dorsal skinfold chamber revealed a strong 
angiogenic response of the skin muscle vascular bed to FGF2 in control mice, evident on 
and from day 3 after stimulation (Figure 20A). Vessel diameters increased markedly in 
small parallel-oriented capillaries and also displayed diameter variability (local dilation and 
narrowing) within the same vessel segment. In contrast, these changes in FGF2-stimulated 
vasculature were more restricted in Rictor
iΔec 
mice (Figure 20A).  
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Figure 20: Rictor 
iΔec
 impedes extensive capillary remodeling and limits the increase in capillary diameters in response 
to FGF2. Stacked frames of representative videos of the capillary vasculature recorded through the dorsal skinfold chamber 
by intravital fluorescence microscopy are shown. (A) Skin muscle capillary structure from day 0 (baseline, 20x 
magnification), day 3 (after wound sealing with FGF2/heparin‐loaded Matrigel, 20x magnification), day 7 (20x) in control 
(left micrographs) and Rictor 
iΔec
 mice (right micrographs). After 7 days of FGF2‐stimulation, control mice exhibit an 
extensively remodeled vascular bed, with rather tortuous and heterogeneous capillary structure. In Rictor 
iΔec
 mice, FGF2‐
induced remodeling is more subtle and retained parallel oriented vessels. (B) Quantification of capillary diameter 
demonstrates marked and significant limitation of capillary diameter increase from day 3 until end of observation period on 
day 7 in Rictor 
iΔec 
compared to control mice. No differences were detected in capillary number and number of branching point 
between control and Rictor 
iΔec 
mice (Control n=8, Rictor 
iΔec 
=9). 
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 From day 3 on, the vascular bed of control mice displayed extensive remodeling in 
response to FGF2, i.e., further enlargement of capillary diameters and development of 
tortuous and bulbous vascular structures that were observed also on levels above the 
capillary bed in draining arterioles and venules (Figure 20A day 7). In Rictor
iΔec 
mice the 
vascular bed showed a more restrained and different mode of remodeling. Capillary 
diameters stopped to increase after day 2 of FGF2-stimulation. Interestingly thin connecting 
anastomoses emerged between capillaries and draining arterioles in Rictor
iΔec 
mice. These 
interconnections formed a lumen as evidenced by the presence of FITC-dextran. However 
the anastomoses seemed not to be part of the circulation as no flow was observed (Figure 
20A, day 7). Lower magnification (x10) micrographs display the different vascular 
remodeling patterns between control and Rictor
iΔec 
mice after 7 days of FGF2 stimulation 
(Figure 21). 
 
 
Figure 21: Overview of FGF2‐stimulated capillary bed. Stacked frames of representative videos of the capillary 
vasculature recorded through the dorsal skinfold chamber by intravital fluorescence microscopy (10 x magnifications). 
Control animals exhibit a more heterogeneous and aberrant vasculature with dilated vessels and capillaries, while the Rictor
iΔec 
mice present a more physiologic appearance with most capillaries retaining their parallel orientation and small increases in 
capillary diameters 
 
 
 
74 
 
 Vascular morphological parameters were quantified taking only perfused vessels 
into the account. Vessel diameters ranged from 4 to 16 μm, thus representing typical 
capillary microvasculature (Figure 20B). We observed that capillary numbers and 
branching points increased slightly in both experimental groups. Importantly, quantification 
displayed a steady increase of capillary diameters in control mice peaking on day 4, while 
capillary dilation in Rictor
iΔec 
mice reached its upper limit on day 2 of FGF2 stimulation. 
From day 3 until the end of the observation period on day 7, capillary diameters were 
significantly smaller (ca. 3 μm) in Rictor
iΔec 
mice compared to control mice (n=9; P>0.05).  
 
3. B.2.4.1. Capillary diameter distribution analysis 
 
Analysis of the distribution of capillary diameters showed that control animals react 
to FGF2 stimulation with a significant increase in the capillary diameter from day 4 until 
day 7 of stimulation compared to un-stimulated control mice on the corresponding days. 
Thus, vascular changes were FGF2-specific. Furthermore, when compared to un-stimulated 
controls, the FGF2 response generated a wide spread of capillary diameter sizes ranging 
from approximately 5 to 20 μm (Figures 22/23). Deletion of endothelial Rictor appeared to 
completely suppress FGF2-induced changes when compared to un-stimulated controls on 
day 4 and 7. Thus, FGF2-stimulated vasculature in Rictor
iΔec 
mice is similar and statistically 
not different to the un-stimulated vasculature in control mice. Furthermore capillary 
diameter distribution remained as narrow as in controls with the peak only slightly moving 
towards larger capillary diameters. Thus capillary diameter range was confined 
approximately between 4 and 12 μm in Rictor
iΔec 
mice (Figures 22/23). We therefore 
conclude that FGF2 induced capillary diameter increase crucially requires endothelial 
mTORC2.  
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Figure 22. Un-stimulated and FGF2 stimulated vascular bed of Rictor
iΔec 
mice exhibit the same behavior 
in capillary diameter increase. Distribution of all capillary diameter values describes the more heterogeneous 
vasculature of control animal and the significant increase when stimulated with FGF2. The Rictor
iΔec 
mice 
present a less spread capillary diameter distribution and equal average capillary diameter between un-stimulated 
and FGF2 stimulated vascular beds on day 4 and 7. 
 
 
 
 
Figure 23: Capillary diameter distribution comparing the changes in capillary diameter in each animal 
group. Control mice show a shift in capillary diameter when stimulated with FGF2 and the include capillaries 
with wide range of different diameters. Rictor
iΔec 
mice show identical behavior in capillary diameter distribution 
regardless the presence of the stimulus. 
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3. B.2.4.2. CD31 and Cre-ER
T2
 staining of FGF2 challenged skin muscle vasculature 
 
Intravital microscopy is limited when focusing on different depths of the 
vasculature due to visibility issues. We therefore performed histological sections from the 
skin muscle at the end of intravital microscopy on day 7. The previously analyzed skin 
muscle tissue was removed, paraffin embedded, cut vertically and stained with the 
endothelial specific marker CD31. The peroxidase CD31 staining confirmed the data of the 
intravital microscopy with the control animals present capillaries around skin muscle with 
wider lumina in comparison to the Rictor
iΔec 
mice (Figure 24). 
 
 
 
Figure 24: CD31 immunohistological staining of skin muscle capillaries. Vertical sections of paraffin 
embedded skin muscle after 7 days of FGF2 stimulation. Control animals have capillaries and vessels around the 
skin muscle with wider lumen than the Rictor 
iΔEC
. 
 
Vertical sections of the skin muscle from Cre
+
; Rictor lox mice were stained for the 
Estrogen Receptor α. Cre-ERT2 that is expressed in these mice and drives the excision of 
Rictor exons is a fused Cre recombinase with the Estrogen Receptor α. A positive staining 
of the Estrogen Receptor α is an indirect proof of Cre recombinase presence and expression 
(185-187). The presence of Cre-ER
T2 
in animals is an additional measure and confirmation 
of the Rictor knockout efficiency. Figure 25 is a representative example of Estrogen 
77 
 
Receptor α staining that is located and restricted to the vasculature. The skin muscle 
displays auto-fluorescence (Figure 25) (188).  
  
   
 
 
 
 
 
Figure 25: Cre-ER
T2
 positive expression in the skin muscle vasculature. Vertical section of FGF2 stimulated 
skin muscle vasculature positively stained for Estrogen receptor α (ER
T2
) which is conjugated with Cre 
recombinase. Positive staining is localized in the capillaries. 
 
3. B.3. Assessment of the role of endothelial mTORC2 in FGF2 induced de novo 
angiogenesis 
   
The effect of endothelial mTORC2 deficiency in FGF2-induced neovascularization 
in vivo was assessed using the Matrigel plug angiogenesis assay. Matrigel was injected 
subcutaneously in the mouse flank with 1, 5 μg/ml FGF2/heparin or diluent (heparin). 7 
days post injection mice were sacrificed and Matrigel plugs were removed (Figure 26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Matrigel plug assay. Ice cold liquid Matrigel is subcutaneously injected and solidifies creating a 
plug attached to the host tissue. Host vasculature and stroma grows on and into the FGF2-loaded Matrigel plug 
in both animal groups. 
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The diluent plugs were used as control for a potential effect of the host animal to 
Matrigel itself which contains a reduced amount of growth factors. As can be seen in Figure 
27 the diluent plugs from both control and Rictor
iΔec 
animals were transparent with no 
obvious vascularization or tissue growth. Absence of vascularization was confirmed by 
histological analysis of Hematoxylene and CD31 immunological staining (data not shown).  
Blood containing microvessels and signs of hemorrhage were macroscopically evident in 
plugs containing FGF2 from control mice compared to rather homogenous, unobtrusive 
vascularization in plugs from Rictor
 iΔec
 mice (Figure 27). 
 
 
Figure 27 Neovascularization of FGF2 containing Matrigel plugs is reduced in Rictor 
iΔec 
mice. 
Matrigel containing heparin (diluent) or 1.5μg/ml FGF2 with heparin (FGF2) was injected subcutaneously into the ventral 
flank of 8-week-old male control and Rictor
iΔec 
mice. The plugs were removed 7 days later and analyzed. Representative 
macro-photographs (scale bar = 1mm) of Matrigel plugs from control (left panels) and Rictor 
iΔec 
mice (right panels) are 
displayed. 
 
3. B.3.1. Endothelial Rictor knockout hampers the vascularization of FGF2 loaded 
Matrigel plugs 
  
Histological sections and CD31 immunohistochemical staining of the capillaries 
revealed the growth and the invasion pattern of the host capillaries into the FGF2-
containing plugs. The histological analysis showed that capillaries invade on average to 
about 800 μm from the surface of the plug into the center, whereas microvessels from 
Rictor
 iΔec
 
1mm 
control   
FGF2  Diluent  FGF2  Diluent  
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Rictor 
iΔec 
mice invaded plugs only to about 300 μm (P<0.05; n=4/7) (Figure 28, upper 
micrographs and quantification to the right). 
 
 
 
Figure28: Rictor 
iΔec 
hampers the invasion of host capillaries and the vascularization of FGF2 containing Matrigel 
plugs (A) Paraffin‐embedded FGF2 containing plugs were sectioned horizontally (see dashed lines in Fig. 12) and immune‐
stained for CD31 (brown) and Hematoxylene (blue/nuclei). Upper representative micrographs show 10x magnification (scale 
bar = 200 μm) and display the invasion depth of newly ingrown microvessels from the surface towards center of the Matrigel 
plug. Lower micrographs show 40x magnification (scale bar = 50 μm) displaying heterogeneity of vessel structure and local 
hemorrhage in plugs from control mice. (B) Quantification displays significant reduction of ingrowth (in μm) of neovessels 
into plugs from Rictor
 iΔec 
compared to control mice (P<0.05, n=4/7). 
 
 
In control plugs, the CD31 positive microvessel structure was heterogeneous with 
large microvascular structures at the periphery of the plug, and smaller capillaries towards 
the center. Erythrocytes containing compartments in the plug indicated leaky vasculature 
and local hemorrhage (Figure 28). In contrast, the microvasculature in FGF2-containing 
plugs from Rictor 
iΔec 
mice was composed of homogenously small capillaries with no 
evident hemorrhage (Figure 28) 
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3. B.3.2. Endothelial Rictor affects diameter of existing stromal capillaries in response 
to FGF2  
  
During the 7 days of FGF2 exposure, the Matrigel plug was encapsulated by a thin 
layer of stromal tissue that also contained arterioles and venules. Quantification of these 
vessels showed similar vessel density in plugs from both experimental groups (data not 
shown). However, the luminal area was significantly smaller in vessels of the stromal 
capsule from Rictor
iΔec 
mice compared to control (Figure 29 P<0.05; n=3). Thus, larger 
stromal vessels were observed in the stromal area of Control FGF2 plug in comparison to 
Rictor 
iΔec 
mice as already seen by intravital microscopy in remodeling of the preexisting 
dermal microvasculature. 
 
 
 
Figure29: Rictor 
iΔec 
hampers dilation of the FGF2 Matrigel plug surrounding stromal capillaries Representative 
micrographs of peripheral stroma covering FGF2‐containing Matrigel plugs from control and Rictor 
iΔec 
mice. The area and 
number of identifiable microvessel lumina were measured. Whereas vessel number did not vary (data not shown), a significant 
reduction of the inner luminal area in stromal vessels from Rictor 
iΔec 
compared to control mice was detected (P<0.5, n=4). 
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4. DISCUSSION 
 
Angiogenesis is a process where new capillaries are formed from pre-existing ones. 
Endothelial cells are the drivers of sprouting angiogenesis since it requires their activation 
when pro-angiogenic stimuli prevail over anti-angiogenic mediators (12, 13). Physiological 
angiogenesis is a process which aims in the appropriate vascularization of a tissue in order 
to meet its metabolic demands or in the revascularization of an injured tissue (70). 
Pathological angiogenesis occurs mainly in proliferative diseases like cancer and vascular 
malformations and is characterized by unbalanced angiogenic growth factor secretion (70).  
The mTOR signaling pathway is a central regulator of cell growth and survival and 
consists of mTORC1 and mTORC2. It has been demonstrated that the dual inhibition of 
both of these complexes has anti-tumor and anti-angiogenic properties, however due to the 
lack of specific mTORC2 inhibitors the contribution of each complex in angiogenesis has 
not been clarified yet (153,157,158). Since the endothelial cell is the driving force of 
sprouting angiogenesis, in this thesis we aim to investigate the role of endothelial mTORC2 
in physiological and growth factor induced angiogenesis using an endothelial specific 
Rictor knockout mouse. Rictor is a specific accessory protein of mTORC2 and its depletion 
will cease mTORC2 signaling.   
The efficiency of the induction of Rictor knockout was demonstrated in the scraped 
aortic endothelium (Figure 1, Results Part A) just before the initiation of the dorsal 
skinfold chamber experiments. The immunohistological staining of Cre-ER
T2
 in the dorsal 
skin muscle from animals included in the study and the significant phenotype observed in 
Rictor
iΔec
 animals with intravital microscopy enforce the statement that the animals included 
in this study were indeed endothelial specific Rictor knockout mice. The problem regarding 
Cre-ER
T2
 expression was detected 1.5 year after the completion of these in vivo experiments 
described in this thesis. 
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 Intravital microscopy of the skin muscle vasculature showed that the deletion of 
Rictor does not affect the homeostasis of unchallenged vasculature (Figure 14). Rictor
iΔec
 
mice present the typical vascularization of the panniculus carnosus with parallel capillaries 
and typical perfusion (Figure 14A) and microvessel density (Figure 14B). 
Unlike adult Rictor
iΔec
 mice, data in our laboratory suggest that endothelial Rictor 
knockout embryos present increased lethality and growth retardation when the knockout is 
induced between E9.5 until E11.5 (Data generated by Dr. Kalus). These results were 
acquired using the inducible knockout model in 2011. The results regarding lethality of 
Rictor
iΔec
 embryos were confirmed by a constitutive model of Rictor deletion in the 
endothelium available in our research group (182) (Data generated by Dr. Humar). During 
embryo development there is a different microenvironment that promotes differentiation of 
hemangioblasts to endothelial and blood cells (189). Different ratio and distribution of 
angiogenic factors (190) could be causing the different response of Rictor knockout 
endothelial cells in the embryo and in wound healing of young adult mice.  We could 
speculate that mTORC2 affects angiogenesis when it is stimulated by specific growth factor 
ratio or above a threshold of growth factor concentrations. Given that mTORC2 is known to 
convey signals from growth factors (103) it could be possible that mTORC2 does not affect 
the vasculature in late stages of physiologic development. 
Stimulation with high dose of FGF2 induced a differential response in adult 
Rictor
iΔec
 mice showing a limited increase in capillary diameter, without changes in the 
microvessel density (Figure 20A). Distribution analysis of the capillary diameters 
demonstrate that Rictor
iΔec
 mice behave similarly when stimulated or not with high dose of 
FGF2 (Figure 22/23). A similar effect of mTORC2 was seen in the diameter of existing 
capillaries of the stroma surrounding the FGF2 loaded Matrigel plugs of the Rictor
iΔec
 mice 
(Figure 29).  
Further investigation is required in order to understand by which mechanism 
endothelial mTORC2 regulates capillary diameter. Nitric oxide synthase (eNOS) expression 
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and function (13) and by consequence NO production and bioavailability (12) are major 
determinants of capillary diameter. The majority of the studies associate these cellular 
parameters with mTORC1. Though it has been demonstrated in vitro that mTORC2 
inhibition in endothelial cells hampers the transcription of eNOS and the production of NO 
a regulator of vasodilation/vasoconstriction (191,192). 
 Important elements in regulation of capillary diameter are the pericyte coverage and 
the structure and the amount of ECM covering a capillary (42). A direct relationship 
between pericyte coverage and mTOR signaling has not been established yet. However a 
study on vascular injury showed that Rapamycin treatment hampers SMC proliferation and 
ECM deposition (193).  
 Intravital microscopy of FGF2 stimulated vasculature also revealed different 
remodeling architecture in Rictor
iΔec
 mice (Figure 20/21). High dose of FGF2 in the 
vasculature of control animals resulted in an aberrant vasculature that lacks the typical 
architecture of panniculus carnosus, with signs of intussusception and capillaries with high 
diameter variability within the same segment (local bulges and stenosis). On the other hand 
Rictor
iΔec
 mice present capillaries with more homogenous diameter distribution within the 
same segment (Figure 20A/21). Interestingly the FGF2 challenged vasculature of Rictor
iΔec
 
mice show capillary-like structures with a lumen but with no functional perfusion (Figure 
20A). 
 A similar phenotype was observed in the endothelial Notch knockout mouse (194). 
These mice present enhanced sprouting angiogenesis and tip cell formation leading to 
excessive but not functional vascularization. Additional experiments in our laboratory have 
shown that FGF2 induced endothelial network formation on Matrigel in vitro is disabled by 
Rictor knockout endothelial cells, however, can be rescued by VEGFA stimulation (Data 
generated by Rok Humar and Fabienne Lehner). Interestingly, disabled FGF2-dependent 
network formation was accomplished by an excessive sprouting in all directions without 
establishing connected segments. 
84 
 
Deletion or silencing of the Dll4 in embryos and adult mice resulted in decreased vascular 
maturation, reduced pericyte recruitment/coverage and defective basement membrane 
deposition (25,195). Additionally these studies show that Dll4 deletion promotes 
endothelial cell proliferation and migration resulting in increased vascular density but with 
defective lumen formation (25,196). A recent study by Skuli et al. in 2012 showed that 
HIF2 down-regulates the expression of Dll4 in HIF2 knockout endothelial cells (196). In 
this study it was also shown that HIF2 regulates endothelial cell proliferation, migration and 
morphogenic event which are translated in vivo to increased vessel formation with poor 
perfusion and functionality (196). Possibly the reduced signaling of Dll4/Notch pathway 
leads to excessive tip cell formation generating multiple sprouts with defective lumens. A 
connection between the above studies with our results comes from the fact that HIFa and 
HIF2 are differentially regulated by mTORC1/2 and mTORC2 respectively (197). An 
investigation regarding of the relationship of mTORC2 signaling with Dll4/Notch and HIF2 
would be very interesting since there are not many available data. 
On a transcriptional level FoxO1and FoxO3a influence and regulate angiogenesis. 
These two transcription factors which are abundantly expressed in endothelial cells regulate 
endothelial cell migration, proliferation and tube formation (199). Increased activation of 
FoxO1/3a hampers all the above cellular functions and suppresses eNOS expression (198).  
mTORC2 is an integral component of the Akt-FoxO signaling pathway (117). We can 
speculate that part of our in vivo phenotype can be attributed to differential activation of the 
FoxO transcription factors due to mTORC2 silencing (117). Akt phosphorylation that is 
mediated by mTORC2 leads to the phosphorylation and inactivation of FoxO1/3a which in 
turn activates angiogenic processes (Data generated by Fabio Aimi. Manuscript in 
preparation: Aimi & Georgiopoulou) (117). Rictor knockout induction possibly keeps 
FoxO1/3a in an active form hampering NO production, proliferation, migration and tube 
formation (198) contributing to our in vivo phenotype related with capillary diameter and 
neovascularization. 
85 
 
Neovascularization of the FGF2 Matrigel plugs was impaired by the absence of 
endothelial mTORC2 (Figure 28). Similar findings were observed in Sirolimus treated rat 
model of hepatocellular carcinoma (199) It was shown that Sirolimus treatment resulted in 
reduced vascularization of the carcinoma and decreased capillary diameter (200) a similar 
finding with ours. Many other studies in tumor growth and vascularization have shown that 
dual inhibition of both mTOR complexes induces a greater inhibition, than inhibiting 
mTORC1 alone (153,157,158). 
The in vivo data collected during this project showed for the first time the 
involvement of endothelial mTORC2 in cellular processes under extreme angiogenic 
conditions. Only when high doses of FGF2 were administered, mTORC2 regulated the 
capillary diameter, the architecture of the remodeled vasculature, and neo-angiogenesis. 
Collectively all the in vivo data suggest for the first time a critical role of endothelial 
mTORC2 in FGF2 induced angiogenesis and vascular remodeling. 
 
Inducible Cre-ER
T2
 mediated recombinase in vivo: Caveats and technical 
considerations 
 
The mouse used in this project was the offspring of breeding a mouse with Ve-
cadherin promoter driving Cre-ER
T2 
recombinase expression (kind donation from Prof. 
Iruella-Arispe, UCLA, California/USA) (168, 170, 182) and a mouse with loxed Rictor 
exons 4 and 5 (168). Cre-ER
T2 
is a Cre recombinase fused with the Estrogen Receptor α that 
specifically binds Tamoxifen and it is constitutively expressed under the transcriptional 
control of Ve-Cadherin promoter (170). 
Rictor knockout was induced at the age of 4 weeks with Tamoxifen injections 
following the protocol of Movoinsin et al. (170) (February 2011). The efficiency of 
knockout induction was assessed by quantifying the mRNA levels of Rictor and Cre-ER
T2
 
in isolated aortic endothelium (Figure 1). The expression levels of Cre-ER
T2
 in the animals 
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were very variable from high to low, however exons 4 and 5 were efficiently excised 
(Figure 1). The animals used for this experiment were 27-week-old (after the end of the 
weight gain study). We monitored the efficiency of Rictor knockout in rather old mice (28 
week) to make sure that endothelial cells that potentially did not recombine, did not 
accumulate during adolescence and adulthood (182). The data of these experiment 
suggested that the recombination and excision of Rictor exons occurred efficiently and 
allowed assessment of the aims of this project on the role of endothelial Rictor in 
angiogenesis in vivo, beginning 1 of March 2011. All the in vivo data described in Results 
part Β were obtained from March 2011 until July 2012. Furthermore, Cre-ERT2 is a fused 
protein with the Estrogen Receptor α: immunohistological staining of this receptor can 
monitor Cre-ER
T2
 expression. Skin muscle sections from the animals included in the dorsal 
skinfold chamber experiments were positively stained for Estrogen Receptor α (Figure 25) 
indicating the active transcription and presence of Cre-ER
T2
 recombinase (189-191).  
One and a half years after the acquisition of the data discussed in the second part of 
the result section, the question about the efficiency or endothelial Rictor knockout induction 
in different tissues of interest that are the subject of investigation arose. Optimization of 
multiple techniques for endothelial cells isolation from lungs was achieved (Results Part 
A).The main goal was the isolation of pure enough endothelial cells, in order to have a clear 
result regarding the efficiency of Rictor knockout induction. The scraping of the aortic 
endothelium showed limitations in reproducibility to show Rictor knockout induction 
(Figure 1/3). However: pure populations of lung endothelial cells revealed that the 
induction of the knockout was not taking place (Figures 8/10/11).  
Cre-ER
T2
 recombinase that is specifically expressed in the endothelium driven by 
Ve-Cadherin promoter should follow similar transcription patterns with the native Ve-
Cadherin. Ve-cadherin is constitutively expressed in the endothelium beginning in E6.5 
(202). It has also been demonstrated that Ve-cadherin mRNA is strongly induced under 
angiogenic conditions (193) and shows increased endogenous protein expression in lung 
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endothelium (193). The lung endothelial cells that were isolated with MACS and cultured in 
growth factor enriched medium showed up-regulation of Ve-Cadherin transcription as 
expected, however this was not matched by the transcription of Cre-ER
T2
 (Figure 29/26). 
These results indicate that the promoter regulating Cre-ER
T2
 expression is not properly 
transcribing the recombinase and thus Rictor knockout is not induced in the endothelium. 
All the above results regarding the induction of Rictor knockout in the endothelium 
and the defective transcription of Cre-ER
T2
 urged us to reconsider the transgene model. We 
thoroughly discussed our troubleshooting processes and results with the generators of the 
VE-Cadherin Cre-ER
T2
 mice (Prof. Luisa Iruella-Arispe, UCLA), and learned that similar 
issues from several other research groups had been reported. The exact reason for this 
instability is not known. However, genomic insertion always bears a random risk of the 
transgene being silenced due to chromosomal position effects (216).  
In order to reinstall a properly working inducible and endothelium-specific Cre-
recombinase model, we followed the advice of Prof. Arispe and are now breeding a 
different VE-Cadherin promoter based Cre-ER
T2
 mouse strain from the Laboratory of Ralph 
Adams (Cdh5(PAC)-CreERT2) (203). This promoter mouse bears a different site of 
transgene insertion. It is reported to have stable Cre recombinase expression and a better 
penetrance particularly in brain tissue. This mouse is currently used by several researchers 
exploring effects of endothelium specific gene deletions (203, 204). Additionally a 
fluorescent reporter mouse (B6.Cg-Gt (ROSA)26Sor<tm9(CAG-tdTomato)Hze>/J) (204) is 
currently being crossed with Cdh5(PAC)-Cre-ER
T2
; Rictor
lox/lox
 mice. The robust native 
fluorescence of this reporter enables direct visualization of Cre-ER
T2
 activity in the 
vasculature during all steps of development and adolescence. Isolation of endothelial cells 
with the above mentioned techniques, preferably magnetic sorting, however is still required 
in order to prove that Cre-ER
T2
 removes the Rictor exons. The combined usage of these two 
approaches would provide solid information about the efficiency of Rictor knockout in the 
endothelium for the future experiments 
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Outlook 
 
Gene expression and proteomic analysis of Rictor knockout endothelial cells will 
possibly reveal important molecules that are regulated by mTORC2 and it will be able to 
propose a molecular mechanism for the observed phenotype. A micro-array in Rictor 
knockout endothelial cells is currently conducted in the laboratory in order to investigate 
the molecular mechanism of our phenotype (Micro-array conducted by Fabio Aimi and 
Christian Schaer. Manuscript in preparation Aimi & Georgiopoulou) 
There is a variety of genetic and acquired pathologies that are characterized by 
extensive and uncontrolled angiogenesis such as atherosclerosis, vascular malformations 
and transplantation induced arteriopathy,  retinopathies, psoriasis, arthritis, obesity and 
inflammatory diseases (205, 206). Last but not least cancer is a disease that is dependent on 
angiogenesis for its growth and metastasis (206) 
 Management and ceasing angiogenesis is an attractive therapeutic target. Anti-
angiogenesis therapies have been designed targeting fundamental signaling pathways of 
angiogenesis, such as VEGF/VEGFR2, PDGF/PDGFR and general inhibitors Tyrosine 
Kinase Receptors. Targeted anti-angiogenesis treatments are mainly used for cancer 
treatment (207). The main drawbacks of targeted anti-angiogenesis treatments is that fact 
that tumors acquire resistance in these therapies by activating alternative pathways to 
sustain their vascularization (7,70,73,77,78) and that provoke serious side effects such as 
hemorrhagic episodes and thrombosis which are difficult to manage (208). 
 mTOR inhibitors gained attention in the last years due to the anti-proliferative and 
anti-angiogenic capacity (7,157). Dissecting the specific role of mTORC2 in physiological 
and pathological angiogenesis could provide additional therapeutic targets.  
The use of mTOR inhibitors has been approved for Renal Cell Carcinoma and 
prolonged the overall survival of the patients. Inhibition of mTORC1 and C2 can re-
sensitize the resistant tumors to the treatment by blocking the PI3K/mTOR pathway (211). 
However in both pre-clinical and clinical studies it is shown that inhibition of these 
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pathways is cytostatic and not cytotoxic leading to stabilization of the disease rather than 
regression (212). The use of Rapamycin and analogues inhibits mainly mTORC1 and can 
provoke resistance due to feedback activation loops and activation of mTORC2 which in 
turn boosts Akt phosphorylation (212). From all the above pre-clinical and clinical studies it 
can be seen that mTOR inhibitors should and are used in combination with other anti-
angiogenesis treatments, standard chemotherapy or radiotherapy (212,213). 
The results acquired from our laboratory show that mTORC2 regulates capillary 
dilation and the remodeling architecture of FGF2 stimulated vasculature. The ablation of 
mTORC2 resulted in a less aberrant vasculature. Visually the overview of the FGF2 
stimulated vasculature resembles a more physiological state. This could provide indirect 
evidence that the ablation of mTORC2 contributes to vascular normalization (209,210). On 
the other hand FGF2 loaded Matrigel plugs showed that the ablation of mTORC2 hampers 
neo-angiogenesis. Thus, inhibition of mTORC2 is an appealing therapeutic target, 
especially for cancer malignancies. However, further investigation is needed in order to 
understand how endothelial mTORC2 inhibition could affect the tumor environment. On 
the other hand data are needed to identify the specific growth factors that signal through 
mTORC2, since not all cancer types are dependent on the same growth factors. If the 
contribution of mTORC2 in vascular normalization can be proven, targeting endothelial 
mTORC2 could open a time window where the vasculature is more functional and 
radiation- and chemotherapy could be more efficient (209).  
 
 
 
 
 
 
 
90 
 
References 
 
1. Dawson, T. H. (2001) Similitude in the cardiovascular system of 
mammals. The Journal of experimental biology 204, 395-407 
 
2. Wagenseil, J. E., and Mecham, R. P. (2009) Vascular extracellular 
matrix and arterial mechanics. Physiological reviews 89, 957-989 
 
3. Udan, R. S., Culver, J. C., and Dickinson, M. E. (2013)  
Understanding vascular development. Wiley Interdiscip Rev Dev Biol 2, 
327-346 
 
4. Chappell, J. C., Wiley, D. M., and Bautch, V. L. (2011) Regulation of 
blood vessel sprouting. Semin Cell Dev Biol 22, 1005-1011 
 
5. Eilken, H. M., and Adams, R. H. (2010) Dynamics of endothelial cell 
behavior in sprouting angiogenesis. Curr Opin Cell Biol 22, 617-625 
 
6. Teixeira, V., Arede, N., Gardner, R., Rodriguez-Leon, J., and 
Tavares, A. T. (2011) Targeting the hemangioblast with a novel cell type-
specific enhancer. BMC developmental biology 11, 76 
 
7. Folkman, J. (2007) Angiogenesis: an organizing principle for drug 
discovery? Nat Rev Drug Discov 6, 273-286 
 
8. Carmeliet, P., De Smet, F., Loges, S., and Mazzone, M. (2009) 
Branching morphogenesis and antiangiogenesis candidates: tip cells lead 
the way. Nat Rev Clin Oncol 6, 315-326 
 
9. Welti, J., Loges, S., Dimmeler, S., and Carmeliet, P. (2013) Recent 
molecular discoveries in angiogenesis and antiangiogenic therapies in 
cancer. The Journal of clinical investigation 123, 3190-3200 
 
10. Singh, S., Wu, B. M., and Dunn, J. C. (2011) The enhancement of 
VEGF-mediated angiogenesis by polycaprolactone scaffolds with surface 
cross-linked heparin. Biomaterials 32, 2059-2069 
 
11. Ennett, A. B., Kaigler, D., and Mooney, D. J. (2006) Temporally 
regulated delivery of VEGF in vitro and in vivo. Journal of biomedical 
materials research. Part A 79, 176-184 
 
12. Carmeliet, P. (2000) Mechanisms of angiogenesis and 
arteriogenesis. Nature medicine 6, 389-395 
 
13. MacLauchlan, S., Yu, J., Parrish, M., Asoulin, T. A., Schleicher, M., 
Krady, M. M., Zeng, J., Huang, P. L., Sessa, W. C., and Kyriakides, T. R. 
(2011) Endothelial nitric oxide synthase controls the expression of the 
angiogenesis inhibitor thrombospondin 2. Proceedings of the National 
Academy of Sciences of the United States of America 108, E1137-1145 
 
14. Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., 
Abramsson, A., Jeltsch, M., Mitchell, C., Alitalo, K., Shima, D., and 
91 
 
Betsholtz, C. (2003) VEGF guides angiogenic sprouting utilizing endothelial 
tip cell filopodia. The Journal of cell biology 161, 1163-1177 
 
15. Ferrara, N. (1999) Vascular endothelial growth factor: molecular and 
biological aspects. Current topics in microbiology and immunology 237, 1-
30 
 
16. Ruhrberg, C., Gerhardt, H., Golding, M., Watson, R., Ioannidou, S., 
Fujisawa, H., Betsholtz, C., and Shima, D. T. (2002) Spatially restricted 
patterning cues provided by heparin-binding VEGF-A control blood vessel 
branching morphogenesis. Genes Dev 16, 2684-2698 
 
17. Gerhardt, H. (2008) VEGF and endothelial guidance in angiogenic 
sprouting. Organogenesis 4, 241-246 
 
18. Chen, T. T., Luque, A., Lee, S., Anderson, S. M., Segura, T., and Iruela-
Arispe, M. L. (2010) Anchorage of VEGF to the extracellular matrix conveys 
differential signaling responses to endothelial cells. The Journal of cell 
biology 188, 595-609 
 
19. Hellstrom, M., Phng, L. K., Hofmann, J. J., Wallgard, E., Coultas, L., 
Lindblom, P., Alva, J., Nilsson, A. K., Karlsson, L., Gaiano, N., Yoon, K., 
Rossant, J., Iruela-Arispe, M. L., Kalen, M., Gerhardt, H., and Betsholtz, C. 
(2007) Dll4 signalling through Notch1 regulates formation of tip cells during 
angiogenesis. Nature 445, 776-780 
 
20. Tung, J. J., Tattersall, I. W., and Kitajewski, J. (2012) Tips, stalks, 
tubes: notch-mediated cell fate determination and mechanisms of 
tubulogenesis during angiogenesis. Cold Spring Harb Perspect Med 2, 
a006601 
 
21. Lobov, I. B., Renard, R. A., Papadopoulos, N., Gale, N. W., 
Thurston, G., Yancopoulos, G. D., and Wiegand, S. J. (2007) Delta-like 
ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic 
sprouting. Proceedings of the National Academy of Sciences of the United 
States of America 104, 3219-3224 
 
22. Leslie, J. D., Ariza-McNaughton, L., Bermange, A. L., McAdow, R., 
Johnson, S. L., and Lewis, J. (2007) Endothelial signalling by the Notch 
ligand Delta-like 4 restricts angiogenesis. Development 134, 839-844 
 
23. Liu, Z. J., Shirakawa, T., Li, Y., Soma, A., Oka, M., Dotto, G. P., 
Fairman, R. M., Velazquez, O. C., and Herlyn, M. (2003) Regulation of 
Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial 
cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell 
Biol 23, 14-25 
 
24. Bentley, K., Gerhardt, H., and Bates, P. A. (2008) Agent-based 
simulation of notch-mediated tip cell selection in angiogenic sprout 
initialisation. J Theor Biol 250, 25-36 
 
25. Benedito, R., Trindade, A., Hirashima, M., Henrique, D., da Costa, L. 
L., Rossant, J., Gill, P. S., and Duarte, A. (2008) Loss of Notch signalling 
induced by Dll4 causes arterial calibre reduction by increasing endothelial 
cell response to angiogenic stimuli. BMC developmental biology 8, 117 
92 
 
 
26. Boscolo, E., Mulliken, J. B., and Bischoff, J. (2011) VEGFR-1 
mediates endothelial differentiation and formation of blood vessels in a 
murine model of infantile hemangioma. Am J Pathol 179, 2266-2277 
 
27. Fischer, C., Mazzone, M., Jonckx, B., and Carmeliet, P. (2008) FLT1 
and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? 
Nat Rev Cancer 8, 942-956 
 
28. Siekmann, A. F., and Lawson, N. D. (2007) Notch signalling limits 
angiogenic cell behaviour in developing zebrafish arteries. Nature 445, 781-
784 
 
29. Shibuya, M. (2006) Differential roles of vascular endothelial growth 
factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39, 
469-478 
 
30. Kappas, N. C., Zeng, G., Chappell, J. C., Kearney, J. B., Hazarika, 
S., Kallianos, K. G., Patterson, C., Annex, B. H., and Bautch, V. L. (2008) 
The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood 
vessel branching. The Journal of cell biology 181, 847-858 
 
31. Chappell, J. C., Taylor, S. M., Ferrara, N., and Bautch, V. L. (2009) 
Local guidance of emerging vessel sprouts requires soluble Flt-1. 
Developmental cell 17, 377-386 
 
32. Krueger, J., Liu, D., Scholz, K., Zimmer, A., Shi, Y., Klein, C., 
Siekmann, A., Schulte-Merker, S., Cudmore, M., Ahmed, A., and le Noble, 
F. (2011) Flt1 acts as a negative regulator of tip cell formation and 
branching morphogenesis in the zebrafish embryo. Development 138, 
2111-2120 
33. Jakobsson, L., Franco, C. A., Bentley, K., Collins, R. T., Ponsioen, 
B., Aspalter, I. M., Rosewell, I., Busse, M., Thurston, G., Medvinsky, A., 
Schulte-Merker, S., and Gerhardt, H. (2010) Endothelial cells dynamically 
compete for the tip cell position during angiogenic sprouting. Nat Cell Biol 
12, 943-953 
 
34. Skobe, M., Hawighorst, T., Jackson, D. G., Prevo, R., Janes, L., 
Velasco, P., Riccardi, L., Alitalo, K., Claffey, K., and Detmar, M. (2001) 
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer 
metastasis. Nature medicine 7, 192-198 
 
35. Tammela, T., Zarkada, G., Wallgard, E., Murtomaki, A., Suchting, 
S., Wirzenius, M., Waltari, M., Hellstrom, M., Schomber, T., Peltonen, R., 
Freitas, C., Duarte, A., Isoniemi, H., Laakkonen, P., Christofori, G., Yla-
Herttuala, S., Shibuya, M., Pytowski, B., Eichmann, A., Betsholtz, C., and 
Alitalo, K. (2008) Blocking VEGFR-3 suppresses angiogenic sprouting and 
vascular network formation. Nature 454, 656-660 
 
36. Tammela, T., Zarkada, G., Nurmi, H., Jakobsson, L., Heinolainen, 
K., Tvorogov, D., Zheng, W., Franco, C. A., Murtomaki, A., Aranda, E., 
Miura, N., Yla-Herttuala, S., Fruttiger, M., Makinen, T., Eichmann, A., 
Pollard, J. W., Gerhardt, H., and Alitalo, K. (2011) VEGFR-3 controls tip to 
stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat 
Cell Biol 13, 1202-1213 
93 
 
 
37. Fantin, A., Vieira, J. M., Gestri, G., Denti, L., Schwarz, Q., 
Prykhozhij, S., Peri, F., Wilson, S. W., and Ruhrberg, C. (2010) Tissue 
macrophages act as cellular chaperones for vascular anastomosis 
downstream of VEGF-mediated endothelial tip cell induction. Blood 116, 
829-840 
 
38. Benedito, R., Rocha, S. F., Woeste, M., Zamykal, M., Radtke, F., 
Casanovas, O., Duarte, A., Pytowski, B., and Adams, R. H. (2012) Notch-
dependent VEGFR3 upregulation allows angiogenesis without VEGF-
VEGFR2 signalling. Nature 484, 110-114 
 
39. Shawber, C. J., Funahashi, Y., Francisco, E., Vorontchikhina, M., 
Kitamura, Y., Stowell, S. A., Borisenko, V., Feirt, N., Podgrabinska, S., 
Shiraishi, K., Chawengsaksophak, K., Rossant, J., Accili, D., Skobe, M., 
and Kitajewski, J. (2007) Notch alters VEGF responsiveness in human and 
murine endothelial cells by direct regulation of VEGFR-3 expression. The 
Journal of clinical investigation 117, 3369-3382 
 
40. Jain, R. K. (2003) Molecular regulation of vessel maturation. Nature 
medicine 9, 685-693 
 
41. Armulik, A., Abramsson, A., and Betsholtz, C. (2005) 
Endothelial/pericyte interactions. Circulation research 97, 512-523 
 
42. Stratman, A. N., and Davis, G. E. (2012) Endothelial cell-pericyte 
interactions stimulate basement membrane matrix assembly: influence on 
vascular tube remodeling, maturation, and stabilization. Microsc Microanal 
18, 68-80 
 
43. Abramsson, A., Lindblom, P., and Betsholtz, C. (2003) Endothelial 
and nonendothelial sources of PDGF-B regulate pericyte recruitment and 
influence vascular pattern formation in tumors. The Journal of clinical 
investigation 112, 1142-1151 
 
44. Bjarnegard, M., Enge, M., Norlin, J., Gustafsdottir, S., Fredriksson, 
S., Abramsson, A., Takemoto, M., Gustafsson, E., Fassler, R., and 
Betsholtz, C. (2004) Endothelium-specific ablation of PDGFB leads to 
pericyte loss and glomerular, cardiac and placental abnormalities. 
Development 131, 1847-1857 
 
45. Lindblom, P., Gerhardt, H., Liebner, S., Abramsson, A., Enge, M., 
Hellstrom, M., Backstrom, G., Fredriksson, S., Landegren, U., Nystrom, H. 
C., Bergstrom, G., Dejana, E., Ostman, A., Lindahl, P., and Betsholtz, C. 
(2003) Endothelial PDGF-B retention is required for proper investment of 
pericytes in the microvessel wall. Genes Dev 17, 1835-1840 
 
46. Benjamin, L. E., Hemo, I., and Keshet, E. (1998) A plasticity window 
for blood vessel remodelling is defined by pericyte coverage of the 
preformed endothelial network and is regulated by PDGF-B and VEGF. 
Development 125, 1591-1598 
 
47. Eklund, L., and Saharinen, P. (2013) Angiopoietin signaling in the 
vasculature. Exp Cell Res 319, 1271-1280 
 
94 
 
48. Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. 
C., Davis, S., Sato, T. N., and Yancopoulos, G. D. (1996) Requisite role of 
angiopoietin-1, a ligand for the TIE2 receptor, during embryonic 
angiogenesis. Cell 87, 1171-1180 
 
49. Sundberg, C., Kowanetz, M., Brown, L. F., Detmar, M., and Dvorak, 
H. F. (2002) Stable expression of angiopoietin-1 and other markers by 
cultured pericytes: phenotypic similarities to a subpopulation of cells in 
maturing vessels during later stages of angiogenesis in vivo. Lab Invest 82, 
387-401 
 
50. Sato, T. N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., 
Fujiwara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., and 
Qin, Y. (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 
in blood vessel formation. Nature 376, 70-74 
 
51. Dumont, D. J., Gradwohl, G., Fong, G. H., Puri, M. C., Gertsenstein, 
M., Auerbach, A., and Breitman, M. L. (1994) Dominant-negative and 
targeted null mutations in the endothelial receptor tyrosine kinase, tek, 
reveal a critical role in vasculogenesis of the embryo. Genes Dev 8, 1897-
1909 
 
52. Iivanainen, E., Nelimarkka, L., Elenius, V., Heikkinen, S. M., Junttila, 
T. T., Sihombing, L., Sundvall, M., Maatta, J. A., Laine, V. J., Yla-Herttuala, 
S., Higashiyama, S., Alitalo, K., and Elenius, K. (2003) Angiopoietin-
regulated recruitment of vascular smooth muscle cells by endothelial-
derived heparin binding EGF-like growth factor. FASEB J 17, 1609-1621 
 
53. Mammoto, T., Parikh, S. M., Mammoto, A., Gallagher, D., Chan, B., 
Mostoslavsky, G., Ingber, D. E., and Sukhatme, V. P. (2007) Angiopoietin-1 
requires p190 RhoGAP to protect against vascular leakage in vivo. The 
Journal of biological chemistry 282, 23910-23918 
 
54. Gavard, J., Patel, V., and Gutkind, J. S. (2008) Angiopoietin-1 
prevents VEGF-induced endothelial permeability by sequestering Src 
through mDia. Developmental cell 14, 25-36 
 
55. Stratman, A. N., Malotte, K. M., Mahan, R. D., Davis, M. J., and 
Davis, G. E. (2009) Pericyte recruitment during vasculogenic tube assembly 
stimulates endothelial basement membrane matrix formation. Blood 114, 
5091-5101 
56. Stratman, A. N., Schwindt, A. E., Malotte, K. M., and Davis, G. E. 
(2010) Endothelial-derived PDGF-BB and HB-EGF coordinately regulate 
pericyte recruitment during vasculogenic tube assembly and stabilization. 
Blood 116, 4720-4730 
 
57. Stratman, A. N., Saunders, W. B., Sacharidou, A., Koh, W., Fisher, 
K. E., Zawieja, D. C., Davis, M. J., and Davis, G. E. (2009) Endothelial cell 
lumen and vascular guidance tunnel formation requires MT1-MMP-
dependent proteolysis in 3-dimensional collagen matrices. Blood 114, 237-
247 
 
58. Saunders, W. B., Bohnsack, B. L., Faske, J. B., Anthis, N. J., 
Bayless, K. J., Hirschi, K. K., and Davis, G. E. (2006) Coregulation of 
95 
 
vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. 
The Journal of cell biology 175, 179-191 
 
59. Sacharidou, A., Koh, W., Stratman, A. N., Mayo, A. M., Fisher, K. E., 
and Davis, G. E. (2010) Endothelial lumen signaling complexes control 3D 
matrix-specific tubulogenesis through interdependent Cdc42- and MT1-
MMP-mediated events. Blood 115, 5259-5269 
 
60. Lafleur, M. A., Handsley, M. M., Knauper, V., Murphy, G., and 
Edwards, D. R. (2002) Endothelial tubulogenesis within fibrin gels 
specifically requires the activity of membrane-type-matrix 
metalloproteinases (MT-MMPs). J Cell Sci 115, 3427-3438 
 
61. Styp-Rekowska, B., Hlushchuk, R., Pries, A. R., and Djonov, V. 
(2011) Intussusceptive angiogenesis: pillars against the blood flow. Acta 
Physiol (Oxf) 202, 213-223 
 
62. Caduff, J. H., Fischer, L. C., and Burri, P. H. (1986) Scanning 
electron microscope study of the developing microvasculature in the 
postnatal rat lung. Anat Rec 216, 154-164 
 
63. Djonov, V., Baum, O., and Burri, P. H. (2003) Vascular remodeling 
by intussusceptive angiogenesis. Cell Tissue Res 314, 107-117 
 
64. Burri, P. H., Hlushchuk, R., and Djonov, V. (2004) Intussusceptive 
angiogenesis: its emergence, its characteristics, and its significance. 
Developmental dynamics : an official publication of the American 
Association of Anatomists 231, 474-488 
 
65. Djonov, V. G., Galli, A. B., and Burri, P. H. (2000) Intussusceptive 
arborization contributes to vascular tree formation in the chick chorio-
allantoic membrane. Anat Embryol (Berl) 202, 347-357 
 
66. Gambino, L. S., Wreford, N. G., Bertram, J. F., Dockery, P., 
Lederman, F., and Rogers, P. A. (2002) Angiogenesis occurs by vessel 
elongation in proliferative phase human endometrium. Hum Reprod 17, 
1199-1206. 
 
67. Makanya, A. N., Hlushchuk, R., and Djonov, V. G. (2009) 
Intussusceptive angiogenesis and its role in vascular morphogenesis, 
patterning, and remodeling. Angiogenesis 12, 113-123 
 
68. Neufeld, G., and Kessler, O. (2008) The semaphorins: versatile 
regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 
8, 632-645 
 
69. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N 
Engl J Med 285, 1182-1186 
70. Kerbel, R. S. (2008) Tumor angiogenesis. N Engl J Med 358, 2039-
2049 
 
71. Quintieri, L., Selmy, M., and Indraccolo, S. (2014) Metabolic effects 
of antiangiogenic drugs in tumors: therapeutic implications. Biochem 
Pharmacol 89, 162-170 
 
96 
 
72. Hlushchuk, R., Riesterer, O., Baum, O., Wood, J., Gruber, G., 
Pruschy, M., and Djonov, V. (2008) Tumor recovery by angiogenic switch 
from sprouting to intussusceptive angiogenesis after treatment with 
PTK787/ZK222584 or ionizing radiation. Am J Pathol 173, 1173-1185 
 
73. Loges, S., Schmidt, T., and Carmeliet, P. (2010) Mechanisms of 
resistance to anti-angiogenic therapy and development of third-generation 
anti-angiogenic drug candidates. Genes Cancer 1, 12-25 
 
74. Bergers, G., and Hanahan, D. (2008) Modes of resistance to anti-
angiogenic therapy. Nat Rev Cancer 8, 592-603 
 
75. Zern, B. J., Chu, H., and Wang, Y. (2010) Control growth factor 
release using a self-assembled [polycation:heparin] complex. PloS one 5, 
e11017 
 
76. Dimova, I., Popivanov, G., and Djonov, V. (2014) Angiogenesis in 
cancer - general pathways and their therapeutic implications. J BUON 19, 
15-21 
 
77. Mittal, K., Ebos, J., and Rini, B. (2014) Angiogenesis and the tumor 
microenvironment: vascular endothelial growth factor and beyond. Semin 
Oncol 41, 235-251 
78. Benazzi, C., Al-Dissi, A., Chau, C. H., Figg, W. D., Sarli, G., de 
Oliveira, J. T., and Gartner, F. (2014) Angiogenesis in spontaneous tumors 
and implications for comparative tumor biology. ScientificWorldJournal 
2014, 919570 
 
79. Gospodarowicz, D. (1974) Localisation of a fibroblast growth factor 
and its effect alone and with hydrocortisone on 3T3 cell growth. Nature 249, 
123-127 
 
80. Murakami, M., and Simons, M. (2008) Fibroblast growth factor 
regulation of neovascularization. Curr Opin Hematol 15, 215-220 
 
81. Alessi, P., Leali, D., Camozzi, M., Cantelmo, A., Albini, A., and 
Presta, M. (2009) Anti-FGF2 approaches as a strategy to compensate 
resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic 
FGF2-antagonist. Eur Cytokine Netw 20, 225-234 
 
82. Lieu, C., Heymach, J., Overman, M., Tran, H., and Kopetz, S. (2011) 
Beyond VEGF: inhibition of the fibroblast growth factor pathway and 
antiangiogenesis. Clin Cancer Res 17, 6130-6139 
 
83. Mignatti, P., Morimoto, T., and Rifkin, D. B. (1992) Basic fibroblast 
growth factor, a protein devoid of secretory signal sequence, is released by 
cells via a pathway independent of the endoplasmic reticulum-Golgi 
complex. J Cell Physiol 151, 81-93 
 
84. Tassi, E., Al-Attar, A., Aigner, A., Swift, M. R., McDonnell, K., 
Karavanov, A., and Wellstein, A. (2001) Enhancement of fibroblast growth 
factor (FGF) activity by an FGF-binding protein. The Journal of biological 
chemistry 276, 40247-40253 
 
97 
 
85. Aigner, A., Butscheid, M., Kunkel, P., Krause, E., Lamszus, K., 
Wellstein, A., and Czubayko, F. (2001) An FGF-binding protein (FGF-BP) 
exerts its biological function by parallel paracrine stimulation of tumor cell 
and endothelial cell proliferation through FGF-2 release. Int J Cancer 92, 
510-517 
 
86. Presta, M., Dell'Era, P., Mitola, S., Moroni, E., Ronca, R., and 
Rusnati, M. (2005) Fibroblast growth factor/fibroblast growth factor receptor 
system in angiogenesis. Cytokine Growth Factor Rev 16, 159-178 
 
87. Seghezzi, G., Patel, S., Ren, C. J., Gualandris, A., Pintucci, G., 
Robbins, E. S., Shapiro, R. L., Galloway, A. C., Rifkin, D. B., and Mignatti, 
P. (1998) Fibroblast growth factor-2 (FGF-2) induces vascular endothelial 
growth factor (VEGF) expression in the endothelial cells of forming 
capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 
141, 1659-1673 
 
88. Rogers, M. S., Rohan, R. M., Birsner, A. E., and D'Amato, R. J. 
(2004) Genetic loci that control the angiogenic response to basic fibroblast 
growth factor. FASEB J 18, 1050-1059 
 
89. Claffey, K. P., Abrams, K., Shih, S. C., Brown, L. F., Mullen, A., and 
Keough, M. (2001) Fibroblast growth factor 2 activation of stromal cell 
vascular endothelial growth factor expression and angiogenesis. Lab Invest 
81, 61-75 
 
90. Tsunoda, S., Nakamura, T., Sakurai, H., and Saiki, I. (2007) 
Fibroblast growth factor-2-induced host stroma reaction during initial tumor 
growth promotes progression of mouse melanoma via vascular endothelial 
growth factor A-dependent neovascularization. Cancer Sci 98, 541-548 
 
91. Magnusson, P., Rolny, C., Jakobsson, L., Wikner, C., Wu, Y., 
Hicklin, D. J., and Claesson-Welsh, L. (2004) Deregulation of Flk-1/vascular 
endothelial growth factor receptor-2 in fibroblast growth factor receptor-1-
deficient vascular stem cell development. J Cell Sci 117, 1513-1523 
 
92. Shi, Y. H., Bingle, L., Gong, L. H., Wang, Y. X., Corke, K. P., and 
Fang, W. G. (2007) Basic FGF augments hypoxia induced HIF-1-alpha 
expression and VEGF release in T47D breast cancer cells. Pathology 39, 
396-400 
 
93. Tille, J. C., Wood, J., Mandriota, S. J., Schnell, C., Ferrari, S., 
Mestan, J., Zhu, Z., Witte, L., and Pepper, M. S. (2001) Vascular endothelial 
growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic 
fibroblast growth factor-induced angiogenesis in vivo and in vitro. J 
Pharmacol Exp Ther 299, 1073-1085 
 
94. Giavazzi, R., Sennino, B., Coltrini, D., Garofalo, A., Dossi, R., 
Ronca, R., Tosatti, M. P., and Presta, M. (2003) Distinct role of fibroblast 
growth factor-2 and vascular endothelial growth factor on tumor growth and 
angiogenesis. Am J Pathol 162, 1913-19263 
 
95. Jih, Y. J., Lien, W. H., Tsai, W. C., Yang, G. W., Li, C., and Wu, L. 
W. (2001) Distinct regulation of genes by bFGF and VEGF-A in endothelial 
cells. Angiogenesis 4, 313-321 
98 
 
 
96. Kano, M. R., Morishita, Y., Iwata, C., Iwasaka, S., Watabe, T., 
Ouchi, Y., Miyazono, K., and Miyazawa, K. (2005) VEGF-A and FGF-2 
synergistically promote neoangiogenesis through enhancement of 
endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 118, 3759-3768 
 
97. Cao, R., Eriksson, A., Kubo, H., Alitalo, K., Cao, Y., and Thyberg, J. 
(2004) Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced 
angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. 
Circulation research 94, 664-670 
 
98. Nissen, L. J., Cao, R., Hedlund, E. M., Wang, Z., Zhao, X., 
Wetterskog, D., Funa, K., Brakenhielm, E., and Cao, Y. (2007) Angiogenic 
factors FGF2 and PDGF-BB synergistically promote murine tumor 
neovascularization and metastasis. The Journal of clinical investigation 117, 
2766-2777 
 
99. Cao, R., Brakenhielm, E., Pawliuk, R., Wariaro, D., Post, M. J., 
Wahlberg, E., Leboulch, P., and Cao, Y. (2003) Angiogenic synergism, 
vascular stability and improvement of hind-limb ischemia by a combination 
of PDGF-BB and FGF-2. Nature medicine 9, 604-613 
 
100. Pickering, J. G., Uniyal, S., Ford, C. M., Chau, T., Laurin, M. A., 
Chow, L. H., Ellis, C. G., Fish, J., and Chan, B. M. (1997) Fibroblast growth 
factor-2 potentiates vascular smooth muscle cell migration to platelet-
derived growth factor: upregulation of alpha2beta1 integrin and disassembly 
of actin filaments. Circulation research 80, 627-637 
 
101. Laplante, M., and Sabatini, D. M. (2009) mTOR signaling at a 
glance. J Cell Sci 122, 3589-3594 
 
102. Laplante, M., and Sabatini, D. M. (2012) mTOR signaling in growth 
control and disease. Cell 149, 274-293 
 
103. Oh, W. J., and Jacinto, E. (2011) mTOR complex 2 signaling and 
functions. Cell cycle 10, 2305-2316 
 
104. Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M. A., Hall, A., 
and Hall, M. N. (2004) Mammalian TOR complex 2 controls the actin 
cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6, 1122-1128 
 
105. Kim, D. H., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K. V., 
Erdjument-Bromage, H., Tempst, P., and Sabatini, D. M. (2003) GbetaL, a 
positive regulator of the rapamycin-sensitive pathway required for the 
nutrient-sensitive interaction between raptor and mTOR. Molecular cell 11, 
895-904 
 
106. Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. 
A., Kuehl, W. M., Gray, N. S., and Sabatini, D. M. (2009) DEPTOR is an 
mTOR inhibitor frequently overexpressed in multiple myeloma cells and 
required for their survival. Cell 137, 873-886 
 
107. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., 
Tokunaga, C., Avruch, J., and Yonezawa, K. (2002) Raptor, a binding 
99 
 
partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177-
189 
 
108. Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., 
Erdjument-Bromage, H., Tempst, P., and Sabatini, D. M. (2002) mTOR 
interacts with raptor to form a nutrient-sensitive complex that signals to the 
cell growth machinery. Cell 110, 163-175 
 
109. Wang, L., Harris, T. E., Roth, R. A., and Lawrence, J. C., Jr. (2007) 
PRAS40 regulates mTORC1 kinase activity by functioning as a direct 
inhibitor of substrate binding. The Journal of biological chemistry 282, 
20036-20044 
 
110. Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, 
S. A., Spooner, E., Carr, S. A., and Sabatini, D. M. (2007) PRAS40 is an 
insulin-regulated inhibitor of the mTORC1 protein kinase. Molecular cell 25, 
903-915 
 
111. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., 
Huang, Q., Qin, J., and Su, B. (2006) SIN1/MIP1 maintains rictor-mTOR 
complex integrity and regulates Akt phosphorylation and substrate 
specificity. Cell 127, 125-137 
 
112. Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., 
Erdjument-Bromage, H., Tempst, P., and Sabatini, D. M. (2004) Rictor, a 
novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-
independent pathway that regulates the cytoskeleton. Current biology : CB 
14, 1296-1302 
 
113. Pearce, L. R., Huang, X., Boudeau, J., Pawlowski, R., Wullschleger, 
S., Deak, M., Ibrahim, A. F., Gourlay, R., Magnuson, M. A., and Alessi, D. 
R. (2007) Identification of Protor as a novel Rictor-binding component of 
mTOR complex-2. The Biochemical journal 405, 513-522 
 
114. Woo, S. Y., Kim, D. H., Jun, C. B., Kim, Y. M., Haar, E. V., Lee, S. I., 
Hegg, J. W., Bandhakavi, S., Griffin, T. J., and Kim, D. H. (2007) PRR5, a 
novel component of mTOR complex 2, regulates platelet-derived growth 
factor receptor beta expression and signaling. The Journal of biological 
chemistry 282, 25604-25612 
 
115. Frias, M. A., Thoreen, C. C., Jaffe, J. D., Schroder, W., Sculley, T., 
Carr, S. A., and Sabatini, D. M. (2006) mSin1 is necessary for Akt/PKB 
phosphorylation, and its isoforms define three distinct mTORC2s. Current 
biology : CB 16, 1865-1870 
116. Yang, Q., Inoki, K., Ikenoue, T., and Guan, K. L. (2006) Identification 
of Sin1 as an essential TORC2 component required for complex formation 
and kinase activity. Genes & development 20, 2820-2832 
 
117. Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., 
Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., and Sabatini, D. M. 
(2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 
reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, 
but not S6K1. Developmental cell 11, 859-871 
 
100 
 
118. Brown, E. J., Albers, M. W., Shin, T. B., Ichikawa, K., Keith, C. T., 
Lane, W. S., and Schreiber, S. L. (1994) A mammalian protein targeted by 
G1-arresting rapamycin-receptor complex. Nature 369, 756-758 
 
119. Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Shin, T. B., and 
Schreiber, S. L. (1995) Control of p70 s6 kinase by kinase activity of FRAP 
in vivo. Nature 377, 441-446 
 
120. Brunn, G. J., Hudson, C. C., Sekulic, A., Williams, J. M., Hosoi, H., 
Houghton, P. J., Lawrence, J. C., Jr., and Abraham, R. T. (1997) 
Phosphorylation of the translational repressor PHAS-I by the mammalian 
target of rapamycin. Science 277, 99-101 
 
121. Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., and 
Sabatini, D. M. (1998) RAFT1 phosphorylation of the translational 
regulators p70 S6 kinase and 4E-BP1. Proceedings of the National 
Academy of Sciences of the United States of America 95, 1432-1437 
 
122. Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., 
Perruzzi, C., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., Lin, 
M. I., Walsh, K., Dvorak, A. M., Briscoe, D. M., Neeman, M., Sessa, W. C., 
Dvorak, H. F., and Benjamin, L. E. (2006) Pathological angiogenesis is 
induced by sustained Akt signaling and inhibited by rapamycin. Cancer cell 
10, 159-170 
 
123. Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J. H., Hsu, P. P., 
Bagley, A. F., Markhard, A. L., and Sabatini, D. M. (2006) Prolonged 
rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22, 
159-168 
 
124. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K. L. (2002) TSC2 is 
phosphorylated and inhibited by Akt and suppresses mTOR signalling. 
Nature cell biology 4, 648-657 
 
125. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., and Pandolfi, 
P. P. (2005) Phosphorylation and functional inactivation of TSC2 by Erk 
implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-
193 
 
126. Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., and Cantley, 
L. C. (2002) Identification of the tuberous sclerosis complex-2 tumor 
suppressor gene product tuberin as a target of the phosphoinositide 3-
kinase/akt pathway. Molecular cell 10, 151-162 
 
127. Potter, C. J., Pedraza, L. G., and Xu, T. (2002) Akt regulates growth 
by directly phosphorylating Tsc2. Nature cell biology 4, 658-665 
 
128. Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., and Blenis, J. 
(2004) Tumor-promoting phorbol esters and activated Ras inactivate the 
tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. 
Proceedings of the National Academy of Sciences of the United States of 
America 101, 13489-13494 
 
129. Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., and Blenis, 
J. (2003) Tuberous sclerosis complex gene products, Tuberin and 
101 
 
Hamartin, control mTOR signaling by acting as a GTPase-activating protein 
complex toward Rheb. Current biology : CB 13, 1259-1268 
 
130. Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., 
Yang, Q., Bennett, C., Harada, Y., Stankunas, K., Wang, C. Y., He, X., 
MacDougald, O. A., You, M., Williams, B. O., and Guan, K. L. (2006) TSC2 
integrates Wnt and energy signals via a coordinated phosphorylation by 
AMPK and GSK3 to regulate cell growth. Cell 126, 955-968 
 
131. Inoki, K., Li, Y., Xu, T., and Guan, K. L. (2003) Rheb GTPase is a 
direct target of TSC2 GAP activity and regulates mTOR signaling. Genes & 
development 17, 1829-1834 
 
132. Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., 
Hafen, E., Witters, L. A., Ellisen, L. W., and Kaelin, W. G., Jr. (2004) 
Regulation of mTOR function in response to hypoxia by REDD1 and the 
TSC1/TSC2 tumor suppressor complex. Genes & development 18, 2893-
2904 
 
133. Duvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., 
Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., Vander 
Heiden, M. G., MacKeigan, J. P., Finan, P. M., Clish, C. B., Murphy, L. O., 
and Manning, B. D. (2010) Activation of a metabolic gene regulatory 
network downstream of mTOR complex 1. Molecular cell 39, 171-183 
 
134. Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. 
C., Kaper, F., Giaccia, A. J., and Abraham, R. T. (2002) Regulation of 
hypoxia-inducible factor 1alpha expression and function by the mammalian 
target of rapamycin. Molecular and cellular biology 22, 7004-7014 
 
135. Ikenoue, T., Inoki, K., Yang, Q., Zhou, X., and Guan, K. L. (2008) 
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, 
maturation and signalling. The EMBO journal 27, 1919-1931 
 
136. Partovian, C., Ju, R., Zhuang, Z. W., Martin, K. A., and Simons, M. 
(2008) Syndecan-4 regulates subcellular localization of mTOR Complex2 
and Akt activation in a PKCalpha-dependent manner in endothelial cells. 
Molecular cell 32, 140-149 
 
137. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. 
(2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR 
complex. Science 307, 1098-1101 
 
138. Facchinetti, V., Ouyang, W., Wei, H., Soto, N., Lazorchak, A., Gould, 
C., Lowry, C., Newton, A. C., Mao, Y., Miao, R. Q., Sessa, W. C., Qin, J., 
Zhang, P., Su, B., and Jacinto, E. (2008) The mammalian target of 
rapamycin complex 2 controls folding and stability of Akt and protein kinase 
C. The EMBO journal 27, 1932-1943 
 
139. Hauge, C., Antal, T. L., Hirschberg, D., Doehn, U., Thorup, K., 
Idrissova, L., Hansen, K., Jensen, O. N., Jorgensen, T. J., Biondi, R. M., 
and Frodin, M. (2007) Mechanism for activation of the growth factor-
activated AGC kinases by turn motif phosphorylation. The EMBO journal 
26, 2251-2261 
 
102 
 
140. Lee, K., Gudapati, P., Dragovic, S., Spencer, C., Joyce, S., Killeen, 
N., Magnuson, M. A., and Boothby, M. (2010) Mammalian target of 
rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell 
subsets via distinct signaling pathways. Immunity 32, 743-753 
 
141. Gould, C. M., Kannan, N., Taylor, S. S., and Newton, A. C. (2009) 
The chaperones Hsp90 and Cdc37 mediate the maturation and stabilization 
of protein kinase C through a conserved PXXP motif in the C-terminal tail. 
The Journal of biological chemistry 284, 4921-4935 
 
142. Lang, F., Bohmer, C., Palmada, M., Seebohm, G., Strutz-Seebohm, 
N., and Vallon, V. (2006) (Patho)physiological significance of the serum- 
and glucocorticoid-inducible kinase isoforms. Physiological reviews 86, 
1151-1178 
 
143. Garcia-Martinez, J. M., and Alessi, D. R. (2008) mTOR complex 2 
(mTORC2) controls hydrophobic motif phosphorylation and activation of 
serum- and glucocorticoid-induced protein kinase 1 (SGK1). The 
Biochemical journal 416, 375-385 
 
144. Marzec, M., Kasprzycka, M., Liu, X., El-Salem, M., Halasa, K., 
Raghunath, P. N., Bucki, R., Wlodarski, P., and Wasik, M. A. (2007) 
Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-
sensitive mTOR signaling pathway. Oncogene 26, 5606-5614 
 
145. Drenan, R. M., Liu, X., Bertram, P. G., and Zheng, X. F. (2004) 
FKBP12-rapamycin-associated protein or mammalian target of rapamycin 
(FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi 
apparatus. The Journal of biological chemistry 279, 772-778 
 
146. Del Bufalo, D., Ciuffreda, L., Trisciuoglio, D., Desideri, M., Cognetti, 
F., Zupi, G., and Milella, M. (2006) Antiangiogenic potential of the 
Mammalian target of rapamycin inhibitor temsirolimus. Cancer research 66, 
5549-5554 
 
147. Roy, D., Sin, S. H., Lucas, A., Venkataramanan, R., Wang, L., 
Eason, A., Chavakula, V., Hilton, I. B., Tamburro, K. M., Damania, B., and 
Dittmer, D. P. (2013) mTOR inhibitors block Kaposi sarcoma growth by 
inhibiting essential autocrine growth factors and tumor angiogenesis. 
Cancer research 73, 2235-2246 
 
148. Du, W., Gerald, D., Perruzzi, C. A., Rodriguez-Waitkus, P., Enayati, 
L., Krishnan, B., Edmonds, J., Hochman, M. L., Lev, D. C., and Phung, T. L. 
(2013) Vascular tumors have increased p70 S6-kinase activation and are 
inhibited by topical rapamycin. Laboratory investigation; a journal of 
technical methods and pathology 93, 1115-1127 
 
149. Frost, P., Berlanger, E., Mysore, V., Hoang, B., Shi, Y., Gera, J., and 
Lichtenstein, A. (2013) Mammalian target of rapamycin inhibitors induce 
tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and 
angiogenesis. Journal of oncology 2013, 897025 
 
150. Frost, P., Shi, Y., Hoang, B., and Lichtenstein, A. (2007) AKT activity  
ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in 
multiple myeloma cells. Oncogene 26, 2255-2262 
103 
 
 
151. Ishikawa, D., Takeuchi, S., Nakagawa, T., Sano, T., Nakade, J., 
Nanjo, S., Yamada, T., Ebi, H., Zhao, L., Yasumoto, K., Nakamura, T., 
Matsumoto, K., Kagamu, H., Yoshizawa, H., and Yano, S. (2013) mTOR 
inhibitors control the growth of EGFR mutant lung cancer even after 
acquiring resistance by HGF. PloS one 8, e62104 
 
152. Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., 
Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., Jauch, K. 
W., and Geissler, E. K. (2002) Rapamycin inhibits primary and metastatic 
tumor growth by antiangiogenesis: involvement of vascular endothelial 
growth factor. Nature medicine 8, 128-135 
 
153. Falcon, B. L., Barr, S., Gokhale, P. C., Chou, J., Fogarty, J., 
Depeille, P., Miglarese, M., Epstein, D. M., and McDonald, D. M. (2011) 
Reduced VEGF production, angiogenesis, and vascular regrowth contribute 
to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer 
research 71, 1573-1583 
 
154. Pignochino, Y., Dell'Aglio, C., Basirico, M., Capozzi, F., Soster, M., 
Marchio, S., Bruno, S., Gammaitoni, L., Sangiolo, D., Torchiaro, E., 
D'Ambrosio, L., Fagioli, F., Ferrari, S., Alberghini, M., Picci, P., Aglietta, M., 
and Grignani, G. (2013) The Combination of Sorafenib and Everolimus 
Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical 
models. Clinical cancer research : an official journal of the American 
Association for Cancer Research 19, 2117-2131 
 
155. Xue, Q., Hopkins, B., Perruzzi, C., Udayakumar, D., Sherris, D., and 
Benjamin, L. E. (2008) Palomid 529, a novel small-molecule drug, is a 
TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, 
and vascular permeability. Cancer research 68, 9551-9557 
 
156. Xu, S., Li, S., Guo, Z., Luo, J., Ellis, M. J., and Ma, C. X. (2013) 
Combined targeting of mTOR and AKT is an effective strategy for basal-like 
breast cancer in patient-derived xenograft models. Molecular cancer 
therapeutics 12, 1665-1675 
 
157. Fokas, E., Im, J. H., Hill, S., Yameen, S., Stratford, M., Beech, J., 
Hackl, W., Maira, S. M., Bernhard, E. J., McKenna, W. G., and Muschel, R. 
J. (2012) Dual inhibition of the PI3K/mTOR pathway increases tumor 
radiosensitivity by normalizing tumor vasculature. Cancer research 72, 239-
248 
158. Fokas, E., Yoshimura, M., Prevo, R., Higgins, G., Hackl, W., Maira, 
S. M., Bernhard, E. J., McKenna, W. G., and Muschel, R. J. (2012) NVP-
BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian 
target of rapamycin inhibitors, enhance tumor and endothelial cell 
radiosensitivity. Radiation oncology (London, England) 7, 48 
 
159. Bernardi, R., Guernah, I., Jin, D., Grisendi, S., Alimonti, A., Teruya-
Feldstein, J., Cordon-Cardo, C., Simon, M. C., Rafii, S., and Pandolfi, P. P. 
(2006) PML inhibits HIF-1alpha translation and neoangiogenesis through 
repression of mTOR. Nature 442, 779-785 
 
104 
 
160. Dodd, K. M., Yang, J., Shen, M. H., Sampson, J. R., and Tee, A. R. 
(2014) mTORC1 drives HIF-1alpha and VEGF-A signalling via multiple 
mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene  
 
161. Nayak, B. K., Feliers, D., Sudarshan, S., Friedrichs, W. E., Day, R. 
T., New, D. D., Fitzgerald, J. P., Eid, A., Denapoli, T., Parekh, D. J., Gorin, 
Y., and Block, K. (2013) Stabilization of HIF-2alpha through redox 
regulation of mTORC2 activation and initiation of mRNA translation. 
Oncogene 32, 3147-3155 
 
162. Li, W., Petrimpol, M., Molle, K. D., Hall, M. N., Battegay, E. J., and 
Humar, R. (2007) Hypoxia-induced endothelial proliferation requires both 
mTORC1 and mTORC2. Circulation research 100, 79-87 
 
163. Humar, R., Kiefer, F. N., Berns, H., Resink, T. J., and Battegay, E. J. 
(2002) Hypoxia enhances vascular cell proliferation and angiogenesis in 
vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16, 771-780 
 
164. Liegl, R., Koenig, S., Siedlecki, J., Haritoglou, C., Kampik, A., and 
Kernt, M. (2014) Temsirolimus inhibits proliferation and migration in retinal 
pigment epithelial and endothelial cells via mTOR inhibition and decreases 
VEGF and PDGF expression. PloS one 9, e88203 
 
165. Dormond, O., Madsen, J. C., and Briscoe, D. M. (2007) The effects 
of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial 
cells. The Journal of biological chemistry 282, 23679-23686 
 
166. Dada, S., Demartines, N., and Dormond, O. (2008) mTORC2 
regulates PGE2-mediated endothelial cell survival and migration. 
Biochemical and biophysical research communications 372, 875-879 
 
167. Zhuang, G., Yu, K., Jiang, Z., Chung, A., Yao, J., Ha, C., Toy, K., 
Soriano, R., Haley, B., Blackwood, E., Sampath, D., Bais, C., Lill, J. R., and 
Ferrara, N. (2013) Phosphoproteomic analysis implicates the mTORC2-
FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine 
kinases. Sci Signal 6, ra25 
 
168. Bentzinger, C. F., Romanino, K., Cloetta, D., Lin, S., Mascarenhas, 
J. B., Oliveri, F., Xia, J., Casanova, E., Costa, C. F., Brink, M., Zorzato, F., 
Hall, M. N., and Ruegg, M. A. (2008) Skeletal muscle-specific ablation of 
raptor, but not of rictor, causes metabolic changes and results in muscle 
dystrophy. Cell Metab 8, 411-424 
169. Polak, P., Cybulski, N., Feige, J. N., Auwerx, J., Ruegg, M. A., and 
Hall, M. N. (2008) Adipose-specific knockout of raptor results in lean mice 
with enhanced mitochondrial respiration. Cell Metab 8, 399-410 
 
170. Monvoisin, A., Alva, J. A., Hofmann, J. J., Zovein, A. C., Lane, T. F., 
and Iruela-Arispe, M. L. (2006) VE-cadherin-CreERT2 transgenic mouse: a 
model for inducible recombination in the endothelium. Developmental 
dynamics : an official publication of the American Association of Anatomists 
235, 3413-3422 
 
171. Kanda, S., Tomasini-Johansson, B., Klint, P., Dixelius, J., Rubin, K., 
and Claesson-Welsh, L. (1999) Signaling via fibroblast growth factor 
105 
 
receptor-1 is dependent on extracellular matrix in capillary endothelial cell 
differentiation. Exp Cell Res 248, 203-213 
 
172. Smedsrod, B., and Pertoft, H. (1985) Preparation of pure 
hepatocytes and reticuloendothelial cells in high yield from a single rat liver 
by means of Percoll centrifugation and selective adherence. Journal of 
leukocyte biology 38, 213-230 
 
173. Peier, M., Walpen, T., Christofori, G., Battegay, E., and Humar, R. 
(2013) Sprouty2 expression controls endothelial monolayer integrity and 
quiescence. Angiogenesis 16, 455-468 
 
174. Lindenblatt, N., Calcagni, M., Contaldo, C., Menger, M. D., 
Giovanoli, P., and Vollmar, B. (2008) A new model for studying the 
revascularization of skin grafts in vivo: the role of angiogenesis. Plastic and 
reconstructive surgery 122, 1669-1680 
 
175. Rando, T. A., and Blau, H. M. (1994) Primary mouse myoblast 
purification, characterization, and transplantation for cell-mediated gene 
therapy. The Journal of cell biology 125, 1275-1287 
 
176. Springer, M. L., and Blau, H. M. (1997) High-efficiency retroviral 
infection of primary myoblasts. Somatic cell and molecular genetics 23, 
203-209 
 
177. Akhtar, N., Dickerson, E. B., and Auerbach, R. (2002) The 
sponge/Matrigel angiogenesis assay. Angiogenesis 5, 75-80 
 
178. Baumann, C. I., Bailey, A. S., Li, W., Ferkowicz, M. J., Yoder, M. C., 
and Fleming, W. H. (2004) PECAM-1 is expressed on hematopoietic stem 
cells throughout ontogeny and identifies a population of erythroid 
progenitors. Blood 104, 1010-1016 
 
179. Bhattacharya, I., Dragert, K., Albert, V., Contassot, E., Damjanovic, 
M., Hagiwara, A., Zimmerli, L., Humar, R., Hall, M. N., Battegay, E. J., and 
Haas, E. (2013) Rictor in perivascular adipose tissue controls vascular 
function by regulating inflammatory molecule expression. Arteriosclerosis, 
thrombosis, and vascular biology 33, 2105-2111 
 
180. Fehrenbach, M. L., Cao, G., Williams, J. T., Finklestein, J. M., and 
Delisser, H. M. (2009) Isolation of murine lung endothelial cells. American 
journal of physiology. Lung cellular and molecular physiology 296, L1096-
1103 
181. Marelli-Berg, F. M., Peek, E., Lidington, E. A., Stauss, H. J., and 
Lechler, R. I. (2000) Isolation of endothelial cells from murine tissue. 
Journal of immunological methods 244, 205-215 
 
182. Alva, J. A., Zovein, A. C., Monvoisin, A., Murphy, T., Salazar, A., 
Harvey, N. L., Carmeliet, P., and Iruela-Arispe, M. L. (2006) VE-Cadherin-
Cre-recombinase transgenic mouse: a tool for lineage analysis and gene 
deletion in endothelial cells. Developmental dynamics : an official 
publication of the American Association of Anatomists 235, 759-767 
 
183. Paredes-Gamero, E. J., Medeiros, V. P., Farias, E. H., Justo, G. Z., 
Trindade, E. S., Andrade-Lopes, A. L., Godinho, R. O., de Miranda, A., 
106 
 
Ferreira, A. T., Tersariol, I. L., and Nader, H. B. (2010) Heparin induces rat 
aorta relaxation via integrin-dependent activation of muscarinic M3 
receptors. Hypertension 56, 713-721 
 
184. Springer, M. L., Chen, A. S., Kraft, P. E., Bednarski, M., and Blau, H. 
M. (1998) VEGF gene delivery to muscle: potential role for vasculogenesis 
in adults. Molecular cell 2, 549-558 
 
185. Danielian, P. S., White, R., Hoare, S. A., Fawell, S. E., and Parker, 
M. G. (1993) Identification of residues in the estrogen receptor that confer 
differential sensitivity to estrogen and hydroxytamoxifen. Molecular 
endocrinology 7, 232-240 
 
186. Feil, R., Wagner, J., Metzger, D., and Chambon, P. (1997) 
Regulation of Cre recombinase activity by mutated estrogen receptor 
ligand-binding domains. Biochemical and biophysical research 
communications 237, 752-757 
 
187. Leone, D. P., Genoud, S., Atanasoski, S., Grausenburger, R., 
Berger, P., Metzger, D., Macklin, W. B., Chambon, P., and Suter, U. (2003) 
Tamoxifen-inducible glia-specific Cre mice for somatic mutagenesis in 
oligodendrocytes and Schwann cells. Molecular and cellular neurosciences 
22, 430-440 
 
188. Jackson, K. A., Snyder, D. S., and Goodell, M. A. (2004) Skeletal 
muscle fiber-specific green autofluorescence: potential for stem cell 
engraftment artifacts. Stem cells 22, 180-187 
 
189. Red-Horse, K., Crawford, Y., Shojaei, F., and Ferrara, N. (2007) 
Endothelium-microenvironment interactions in the developing embryo and 
in the adult. Developmental cell 12, 181-194 
 
190. Lymboussaki, A., Olofsson, B., Eriksson, U., and Alitalo, K. (1999) 
Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping 
binding sites in embryonic endothelia and distinct sites in differentiated adult 
endothelia. Circulation research 85, 992-999 
 
191. Barilli, A., Visigalli, R., Sala, R., Gazzola, G. C., Parolari, A., Tremoli, 
E., Bonomini, S., Simon, A., Closs, E. I., Dall'Asta, V., and Bussolati, O. 
(2008) In human endothelial cells rapamycin causes mTORC2 inhibition 
and impairs cell viability and function. Cardiovascular research 78, 563-571 
 
192. Kim, J. A., Jang, H. J., Martinez-Lemus, L. A., and Sowers, J. R. 
(2012) Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-
stimulated endothelial nitric oxide synthase and vasodilation. American 
journal of physiology. Endocrinology and metabolism 302, E201-208 
 
194. Hilker, M., Buerke, M., Guckenbiehl, M., Schwertz, H., Buhler, J., 
Moersig, W., Hake, U., and Oelert, H. (2003) Rapamycin reduces neointima 
formation during vascular injury. VASA. Zeitschrift fur Gefasskrankheiten 
32, 10-13 
 
195. Hofmann, J. J., and Iruela-Arispe, M. L. (2007) Notch signaling in 
blood vessels: who is talking to whom about what? Circulation research 
100, 1556-1568 
107 
 
 
196. Scehnet, J. S., Jiang, W., Kumar, S. R., Krasnoperov, V., Trindade, 
A., Benedito, R., Djokovic, D., Borges, C., Ley, E. J., Duarte, A., and Gill, P. 
S. (2007) Inhibition of Dll4-mediated signaling induces proliferation of 
immature vessels and results in poor tissue perfusion. Blood 109, 4753-
4760 
 
197. Skuli, N., Majmundar, A. J., Krock, B. L., Mesquita, R. C., Mathew, 
L. K., Quinn, Z. L., Runge, A., Liu, L., Kim, M. N., Liang, J., Schenkel, S., 
Yodh, A. G., Keith, B., and Simon, M. C. (2012) Endothelial HIF-2alpha 
regulates murine pathological angiogenesis and revascularization 
processes. The Journal of clinical investigation 122, 1427-1443 
 
198. Toschi, A., Lee, E., Gadir, N., Ohh, M., and Foster, D. A. (2008) 
Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on 
mTORC1 and mTORC2. The Journal of biological chemistry 283, 34495-
34499 
 
199. Potente, M., Urbich, C., Sasaki, K., Hofmann, W. K., Heeschen, C., 
Aicher, A., Kollipara, R., DePinho, R. A., Zeiher, A. M., and Dimmeler, S. 
(2005) Involvement of Foxo transcription factors in angiogenesis and 
postnatal neovascularization. The Journal of clinical investigation 115, 
2382-2392 
 
200. Semela, D., Piguet, A. C., Kolev, M., Schmitter, K., Hlushchuk, R., 
Djonov, V., Stoupis, C., and Dufour, J. F. (2007) Vascular remodeling and 
antitumoral effects of mTOR inhibition in a rat model of hepatocellular 
carcinoma. Journal of hepatology 46, 840-848 
 
201. Cross, M. J., and Claesson-Welsh, L. (2001) FGF and VEGF 
function in angiogenesis: signalling pathways, biological responses and 
therapeutic inhibition. Trends Pharmacol Sci 22, 201-207 
 
202. Lambeng, N., Wallez, Y., Rampon, C., Cand, F., Christe, G., Gulino-
Debrac, D., Vilgrain, I., and Huber, P. (2005) Vascular endothelial-cadherin 
tyrosine phosphorylation in angiogenic and quiescent adult tissues. 
Circulation research 96, 384-391 
 
203. Wang, Y., Nakayama, M., Pitulescu, M. E., Schmidt, T. S., 
Bochenek, M. L., Sakakibara, A., Adams, S., Davy, A., Deutsch, U., Luthi, 
U., Barberis, A., Benjamin, L. E., Makinen, T., Nobes, C. D., and Adams, R. 
H. (2010) Ephrin-B2 controls VEGF-induced angiogenesis and 
lymphangiogenesis. Nature 465, 483-486 
 
204. Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S. W., Zariwala, H. 
A., Gu, H., Ng, L. L., Palmiter, R. D., Hawrylycz, M. J., Jones, A. R., Lein, E. 
S., and Zeng, H. (2010) A robust and high-throughput Cre reporting and 
characterization system for the whole mouse brain. Nature neuroscience 
13, 133-140 
 
205. Timar, J., Dome, B., Fazekas, K., Janovics, A., and Paku, S. (2001) 
Angiogenesis-dependent diseases and angiogenesis therapy. Pathology 
oncology research : POR 7, 85-94 
 
108 
 
206. Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., 
De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., Scholz, D., Acker, T., 
DiPalma, T., Dewerchin, M., Noel, A., Stalmans, I., Barra, A., Blacher, S., 
VandenDriessche, T., Ponten, A., Eriksson, U., Plate, K. H., Foidart, J. M., 
Schaper, W., Charnock-Jones, D. S., Hicklin, D. J., Herbert, J. M., Collen, 
D., and Persico, M. G. (2001) Synergism between vascular endothelial 
growth factor and placental growth factor contributes to angiogenesis and 
plasma extravasation in pathological conditions. Nature medicine 7, 575-
583 
 
207. Bellou, S., Pentheroudakis, G., Murphy, C., and Fotsis, T. (2013) 
Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer letters 
338, 219-228 
 
208. Elice, F., and Rodeghiero, F. (2012) Hematologic malignancies and 
thrombosis. Thrombosis research 129, 360-366 
 
209. Jain, R. K. (2013) Normalizing tumor microenvironment to treat 
cancer: bench to bedside to biomarkers. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 31, 2205-2218 
 
210. Huang, Y., Goel, S., Duda, D. G., Fukumura, D., and Jain, R. K. 
(2013) Vascular normalization as an emerging strategy to enhance cancer 
immunotherapy. Cancer research 73, 2943-2948 
 
211. Fruman, D. A., and Rommel, C. (2014) PI3K and cancer: lessons, 
challenges and opportunities. Nat Rev Drug Discov 13, 140-156 
 
212. Wander, S. A., Hennessy, B. T., and Slingerland, J. M. (2011) Next-
generation mTOR inhibitors in clinical oncology: how pathway complexity 
informs therapeutic strategy. The Journal of clinical investigation 121, 1231-
1241 
 
213. Husseinzadeh, N., and Husseinzadeh, H. D. (2014) mTOR inhibitors 
and their clinical application in cervical, endometrial and ovarian cancers: a 
critical review. Gynecologic oncology 133, 375-381 
 
214. Dreaden, E. C., Austin, L. A., Mackey, M. A., and El-Sayed, M. A. 
(2012) Size matters: gold nanoparticles in targeted cancer drug delivery. 
Therapeutic delivery 3, 457-478 
 
215. Pallet, N., and Legendre, C. (2013) Adverse events associated with 
mTOR inhibitors. Expert opinion on drug safety 12, 177-186 
 
216.    Oleg E. Tolmachov, Tatiana Subkhankulova and Tanya Tolmachova 
(2013). Silencing of Transgene Expression: A Gene Therapy Perspective, 
Gene Therapy - Tools and Potential Applications, Dr. Francisco Martin 
(Ed.), ISBN: 978-953-51-1014-9, InTech, DOI: 10.5772/53379. Available 
from: http://www.intechopen.com/books/gene-therapy-tools-and-potential-
applications/silencing-of-transgene-expression-a-gene-therapy-perspective 
 
                                         
 
 
